¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/1/14 ¤U¤È 03:20:53
²Ä 5883 ½g¦^À³
|
¤@¡B2b IGA0,1´Á±æȦôp¤èªk¤@¡G
¨ÌASLAN004 1b mITT IGA0,1=44%=7/16
¨ä¤¤ì¥»«D¶Ç²ÎAD6¦ì¡A°ò缐EASI19ªº»´¯g¡A8¶gªvÀø«á0¦ì¦ì¹FIGA0,1(mITT¤w±Æ°£¡^
Y¨Ì¶Ç²ÎADªvÀø¡]Y1b¿z¿ïÄY®æ±Æ°£«D¶Ç²ÎAD¡^
¦Ü¤Ö4/6¡ã6/6·|¹FIGA0,1
«hIGA0,1±N¦^Âk (7+4)/(16+6)=50% (7+5)/(16+6)=55% (7+6)/(16+6)=60%
¤G¡B2b EASI75´Á±æȦôp¡G ¨ÌASLAN004 1b mITT EASI75=11/16=69%
¨ä¤¤ì¥»«D¶Ç²ÎAD6¦ì¡A°ò缐EASI19ªº»´¯g¡A8¶gªvÀø«á0¦ì¦ì¹FEASI75¡C¡]mITT¤w±Æ°£¡^
Y¨Ì¶Ç²ÎADªvÀø¡]Y1b¿z¿ïÄY®æ±Æ°£«D¶Ç²ÎAD¡^
¦Ü¤Ö5/6¡ã6/6·|¹FEASI75
«hEASI75±N¦^Âk (11¤Q5)/(16+6)=73% (11+6)/(16+6)=77%
¥t¥~¤¤Â_²v3/16=19%
¨Ì¾Ú¤T´Á¤¤Â_²v¶È7%¡ã8% EASI75¡]11+6¡^/¡]16+6-1¡^=81%
81%vs24%(¹ï·Ó组)¡BPÈ<0.001
¤T¡B2b ¦ôIGA0,1 ¤èªk¤G
®Ú¾ÚLebrikizumab 2b EASI75 61%-IGA0,1 45%=16%)
ASLAN004 2b IGA0,1 53%vs15%(¹ï·Ó组)¡BPÈ<0.001
¡X¡XIGA0,1=EASI75-16% 69%-16%=53% 81%-16%=65% |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/1/14 ¤W¤È 11:00:20
²Ä 5882 ½g¦^À³
|
¨Ì¥H¤U2b¸Ñª¼¼ÒÀÀ¡B ³Q¨ÖÁʪ÷额50»õ¬ü¤¸¡B¨CªÑ33.3¬ü¤¸ADR¡B15¸U¤dªÑADRªÑ¥»¡B ¦ô¤µ¦~¦~©³¡B©ú¦~ªì³Q¨ÖÁÊ¡D
IGA0,1¤W¬Ý50%~60%,¥i°l¤W¤G½u¤fªA¥ÎÃĪ«(°ª°Æ§@¥Î)
Ų½Ð¤½¥q¤Å¥²´£°ª¥]¾P³æ»ùªñ24¬ü¤¸/ADR 33/1.4=24¬ü¤¸ ¦p¦¹¤~³Q¨Ö³æ»ù¸û®e©ö¹F33¬ü¤¸¡D
¨ÖÁʪ̦ô»ù¥²°Ñ¦Ò¥«»ù¤Î¨é°Ó¥Ø¼Ð»ù¡D
DERM³Q¨Ö³æ»ù18.75/¥]¾P³æ»ù13.25 =1.4 2020/01DERM ³Q¨ÖÁÊ»ù18.75¬ü¤¸ 2019/02DERM ¥]¾P¼W¸ê»ù13.25¬ü¤¸/ªÑ
¤@¡BASLAN004 2b EASI¥§¡°´T预¦ô¬°76%vs40%(¹ï·Ó²Õ),p<0.001
¨Ì1b mITTx8¶g
EASI¥§¡°73%*16¤H 쥻°ò½uEASI19,6¤H¡BY·íªì¦³¿z¿ï¬°¶Ç²ÎAD±wªÌ
¦ô6¤H¤§EASI¥§¡°´T ¨Ìdupilumab ¤T´Á¸ê®Æ预¦ô¡D ¬°77%/67%x73%=84%
(Dupilumab ¤T´Á¡G °ò½u TRAC§C组/¥§¡EASI25.5,预«á¥§¡EASI°´T77% °ò½u TRAC¤¤组/¥§¡EASI32,预«á¥§¡EASI°67%)
22¤H¤§EASI¥§¡°´T=73%x16+6x84%=76% 2b N=59/59¤H¡B EASI¥§¡°´T 76% (ASLAN004) vs 40% (¹ï·Ó²Õ)¡BP<0.001
¤G¡B2b EASI75´Á±æȦôp¡G ¨ÌASLAN004 1b mITT EASI75=11/16=69%
¨ä¤¤ì¥»«D¶Ç²ÎAD6¦ì¡A°ò缐EASI19ªº»´¯g¡A8¶gªvÀø«á0¦ì¦ì¹FEASI75¡C¡]mITT¤w±Æ°£¡^
Y¨Ì¶Ç²ÎADªvÀø¡]Y1b¿z¿ïÄY®æ±Æ°£«D¶Ç²ÎAD¡^
¦Ü¤Ö5/6¡ã6/6·|¹FEASI75
«hEASI75±N¦^Âk (11¤Q5)/(16+6)=73% (11+6)/(16+6)=77%
¥t¥~¤¤Â_²v3/16=19%
¨Ì¾Ú¤T´Á¤¤Â_²v¶È7%¡ã8% EASI75¡]11+6¡^/¡]16+6-1¡^=81%
81%vs24%(¹ï·Ó组)¡BPÈ<0.001
¤T¡B2b ¦ôIGA0,1=53%vs15%(¹ï·Ó组)¡BPÈ<0.001 IGA0,1=EASI75-16% 69%-16%=53% (®Ú¾ÚLebrikizumab 2b EASI75 61%-IGA0,1 45%=16%) |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/1/13 ¤W¤È 08:14:59
²Ä 5881 ½g¦^À³
|
EASI75/EASI90 VS IGA0,1 Àø®Ä®t²§
¤@¡BDupilumab ¤T´ÁÁ{§É, EASI75 °ª¥XIGA0,1 8%~15%ªº¹F¦¨²v. EASI90 §C©óIGA0,1 2%~6%ªº¹F¦¨²v.
1.SOLO1*Q2w*16¶g EASI75 51% IGA0,1 38%(EASI75 °ª¥XIGA0,1 13%) EASI90 36%
2.SOLO1*Qw*16¶g EASI75 52% IGA0,1 37%(EASI75 °ª¥XIGA0,1 15%) EASI90 33%
3.SOLO2*Q2w*16¶g EASI75 44% IGA0,1 36%(EASI75 °ª¥XIGA0,1 8%) EASI90 30%
4.SOLO1*Qw*16¶g EASI75 48% IGA0,1 36%(EASI75 °ª¥XIGA0,1 12%) EASI90 31%
www.nejm.org/doi/full/10.1056/nejmoa1610020
¤G¡BLebrikizumab ¤T´ÁÁ{§É, EASI75 °ª¥XIGA0,1 16%~18%ªº¹F¦¨²v. EASI90 §C©óIGA0,1 3%~5%ªº¹F¦¨²v.
1.ADV1*Q2w*16¶g EASI75 59% IGA0,1 43%(EASI75 °ª¥XIGA0,1 16%) EASI90 38%
2.ADV2*Qw*16¶g EASI75 51% IGA0,1 33%(EASI75 °ª¥XIGA0,1 18%) EASI90 30%
www.almirall.com/documents/portlet_file_entry/4257831/300322_ORI+Lebri+pres+ENG+%2B+pres+vf.pdf/5ad7034f-0dd9-492f-eb83-1515071417de
¤T.¡BLebrikizumab 2bÁ{§É EASI75 °ª¥XIGA0,1 16%ªº¹F¦¨²v. EASI90 §C©óIGA0,1 1%ªº¹F¦¨²v.
Q2w*16¶g
EASI75 61% IGA0,1 45%(EASI75 °ª¥XIGA0,1 16%) EASI90 44%
jamanetwork.com/journals/jamadermatology/fullarticle/2761466
------------------------ ¥|.ASLAN004 2b 16¶g¹w¦ô
(1)ASLAN004 1b mITT*8 ¶gªvÀø ²Ä8¶gASLAN004, EASI75 69% VS 15%(¹ï·Ó²Õ),®t²§54%------ ²Ä16¶gASLAN004, EASI75 69%~81% VS 24%(¹ï·Ó²Õ),®t²§45%~57%------(¦ôp)
VS Lenrikizumab phs2 *8/16 ¶gªvÀø ²Ä8¶gLenr., EASI75 45% VS 18%(¹ï·Ó²Õ),®t²§27%------(¥Øµø§P¹Ï) ²Ä16¶gLenr.,EASI75 60.6% VS 24.3%(¹ï·Ó²Õ),®t²§36.3%------
(2)ASLAN004 1b mITT*8 ¶gªvÀø ²Ä8¶gIGA0,1 44% VS 15%(¹ï·Ó²Õ),®t²§29%------ ²Ä16¶gIGA0,1 53%~65% VS 15%(¹ï·Ó²Õ),®t²§38%~50%-----(¨Ì¾Úlebrikizumab ©Ò±À¦ô²Ä16¶g,EASI75-IGA0,1¤§¶¡ ®t²§16%)
VS Lenrikizumab phs2 *8/16 ¶gªvÀø ²Ä8¶gLenr., IGA0,1 30% VS 5%(¹ï·Ó²Õ),®t²§25%------(¥Øµø§P¹Ï) ²Ä16¶gLenr.,IGA0,1 44.6% VS 15.3%(¹ï·Ó²Õ),®t²§29.3%------ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/1/12 ¤U¤È 10:01:14
²Ä 5880 ½g¦^À³
|
¨Ì¾ÚLebrikizumab 2b¸Ñª¼«áªºDERM¤½¥q¼W¸ê13.25¬ü¤¸«á¥«È7.7»õ¬ü¤¸¡]13.25¬ü¤¸x5.8¸U¤dªÑªÑ¥»¤@¤@11»õ¬ü¤¸³Q¦¬ÁÊ¡A³æ»ù18.75¬ü¤¸¡^
2019/02/01 Lebrikizumab AD 2b¸Ñª¼¤½¥¬¼Æ¾Ú¡C 2019/02 ¶Ò¸ê1.3»õ¬ü¤¸¡A³æ»ù¡G13.25¬ü¤¸¡C
°²³]ASLAN004 2b ¸Ñª¼«á¶Ò¸ê7¸U¤dªÑADR »ù®æ¡G¨é°Ó¥Ø¼Ð»ù7¬ü¤¸x80%=5.6¬ü¤¸¤@ªÑADR¡]7x5.6x97%=3.8»õ¬ü¤¸¶Ò¸ê²bÃB¡^
²Öpµo¦æ14¸U¤dªÑADRX5.6¬ü¤¸¡×7.8»õ¬ü¤¸¡]ªÑ²¼¥«È¡^
¥H¤W±À¦ô¤µ¦~Q2ASLN ¸Ñª¼¼W¸ê«á¥«È¡A´X¥G©MLebrikizumab ªºDERM 2019/02¸Ñª¼¶Ò¸ê«á¥«È¬Û·í¡C
ASLAN004 1b mITT IGA0,1¥Dn«ü¼Ð x8¶g¶È44% vs 15%¡]¹ï·Ó²Õ¡^¡A¡]®t²§29%¡^ °ßµM¸g4¦~¡AAD¥«³õ©ñ¤j¤T¿¡C
¦ý¦p¤W¤§IGA0,1 Àø®Ä©M¹ï·Ó²Õ®t²§¶È29%¡A¬Û·í©óLebrikizumab¤ÎDupilumab ¦©°£¹ï·Ó²Õ«áÀø®Ä¡C ¨é°Ó©Ò¦ôp7¬ü¤¸¤§¥Ø¼Ð»ù¨Ã¤£Â÷ÃСC ⋯⋯⋯⋯⋯ ASLAN004 2bªºIGA0,1 x16ªvÀø¡A¦ôpÁÙ¶·©¹¤W¦Ü50%¡ã60%¥H¤W¡A¥Ñ8¶g®Éªº44%¡C¡]¥ÑEASI75=69¡ã81%±À¦ô IGA0,1 16¶g¡A¥»À³¸¨¦b50%¡ã60%¡^
¦p¦¹¤~¯à¤j´T´£¤ÉASLAN004. ªº»ùÈ¡A¥B¦ôºâ¨ä¥L¾AÀ³¯g§ó¦³¤O¡C¤~¦³¾÷·|¤W¬Ý60»õ¬ü¤¸ªº³Q¨ÖÁÊ»ù¡C §_«h©MLebrikizumab¬Û·íÀø®Ä³Q¨ÖÁÊ»ùÈ´N§C«Ü¦h¤F¡C±N°¦Ü20»õ¬ü¤¸¥H¤U¡C
©Ò¥H2b¸Ñª¼¼Æ¾ÚYIGA0,1 ¸¨¦b50%¡ã60%ASLN À³¸Ó©M¨é°Ó¨ó°Ó©Ô°ª¥]销»ù¨ì11¡ã16¬ü¤¸¥H¤W¡A±µªñCNTB AD2b ¸Ñª¼«e¡A¥«È¨ì15¡D5¡ã¤u23»õ¬ü¤¸¡A¤~¦X²z¡A³Q¨ÖÁÊ»ù¤~¯à§Ö³t¤ÏÀ³60»õ¬ü¤¸¡C
µùLebrikizumab 2b ¡A IGA0,1 ¦b8¶g 30% 16¶g 45% ¤T´Á52¶g47%
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/1/12 ¤U¤È 03:31:19
²Ä 5879 ½g¦^À³
|
§Æ±æ3¤ë15¤é¥H«e¡A¤½¥¬¨p¶Ò¡A¥B»ù®æ¶W¹L5¡D6x88%¬ü¤¸¡þªÑ¡AADR¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2023/1/12 ¤W¤È 11:35:44
²Ä 5878 ½g¦^À³
|
ASLN004ªº»ùÈ´N®tÁ{ªù¤@¸}¡A¥u¦³¥¿¦Vªº´Á¤¤¼Æ¾Ú¡A¤~¯àÅýªü·à²æÂ÷1¶ô¿úªºµ~¹Ò¡A¥[ªo ! §Ö¤½¥¬§a ! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/1/11 ¤W¤È 10:43:01
²Ä 5877 ½g¦^À³
|
ibmi.taiwan-healthcare.org/zh/news_detail.php?REFDOCTYPID=&REFDOCID=0qfr24fx7mfzw7ko
2020/08/20 ³Â¬Ù²z¤u³]p·s°wµ©¨t²ÎÅý¥Ö¤Uª`®g°ª¿@«×¥Íª«»s¾¯¦¨¬°¥i¯à
¹ê»Ú¥Î©óªvÀø®É¤W©¹©¹½Ñ¦h¨ü¡A¦ý²{¦b³Â¬Ù²z¤u¹Î¶¤¶}µo¥X¤@ºØ²³æ¡B§C¦¨¥»ªº§Þ³N¡AÅý¥¼¨Ó¥Ö¤Uª`®g°ª¿@«×¥Íª«»s¾¯©Î¨ä¥LÀøªkªº¶}µo³£¦¨¬°¥i¯à¡C ¥i¼W¥[180ºØÃĪ«¥ÑIVÀR¯ßª`®g §ï¬°SC:¥Ö¤Uª`®g.
·s°wµ©¨t²Î¤À¤º¥~¨âµ©, ¤ºµ©¸Ë°ª¿@«×¥Íª«»s¾¯, ¥~µ©¸Ë¼í·Æ²G, ,¥i´î¤Ö1/7 ª`®g¤O |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/1/10 ¤U¤È 04:02:49
²Ä 5876 ½g¦^À³
|
¸Ø±i¤j¡A
clinicaltrials.gov/ct2/show/NCT04146363
clinicaltrials.gov/ct2/show/NCT04178967?term=Evaluation+of+the+Efficacy+and+Safety+of+Lebrikizumab+%28LY3650150%29+in+Moderate+to+Severe+Atopic+Dermatitis&draw=2&rank=1
¥H¤WLebrikizumab 2Ó¡A¤T´ÁÁ{§É¶}©l¬ã¨s®É¶¡¬O2019/09¡þ24¡A2019/10/29¡A¦U¬ù450¤H¡A¦Xpªñ900¤H¡C
¦³16¶g¬°¥Dn«ü¼Ð ¥t¥~¦³©µ¦ù¦Ü52¶gªvÀø³¡¥÷
2020/01/10 Âù¤è«Å¥¬11¬ü¤¸¨ÖÁÊ¡A¤T´Á¤w¸g¶}3¡ã4Ó¤ë¡C Lily ¤½¥q¶}©lµû¦ô¥Î¤F11Ӥ몺®É¶¡¡C¤]´N¬O»¡Lebrikizumab 2b ¸Ñª¼¼Æ¾Ú¥X¨Ó«á¡A¤~¶}©lµû¦ô¡C
¨ÖÁʮɹïAD¬Û¹ï±M·~ªº¹Î¶¤¬O³Q¨ÖÁʪºDERM¤½¥q¡C
A Study of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroids in Japanese Participants With Moderate-to-Severe Atopic Dermatitis (ADhere-J) 2021/03/10 N=280 ¤H¡ALebrikizumab ¤Q TCS ¤T´ÁÁ{§É
¦Ü©ó¤½¥q²bÈ·íµM·|³Qºâ¤J³Q¨ÖÁʵû¦ô»ùȤ¤¡CÂù¤è³£¦³·|p®v§âÃö¡C
¯à°µ¤T´Á¤~¦³°ª»ùȳQ¨ÖÁÊ¡I
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GPica10150664 |
µoªí®É¶¡:2023/1/10 ¤U¤È 03:37:10
²Ä 5875 ½g¦^À³
|
½Ð°Ý¡A§Ú¤µ¤Ñ¦¬¨ì1/31n¶}ªÑªF·|ªº¸ê®Æ¡A»Ýn²z¥¦¶Ü? ^¤å¤£¬O«Ü¦n¡A¤£¤Óª¾¹D¦b»¡¤°»ò¡A¥uª¾¹DªÑ¥»nÅÜ°Ê¡A¦ý¤£À´Åܰʫᦳ¤°»ò¼vÅT¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2023/1/10 ¤U¤È 02:04:37
²Ä 5874 ½g¦^À³
|
¨âÂIºÃ°Ý½Ð±Ð¡G 1.¦p¤Ñ©R¤j¤j©Òz(10141925 µoªí®É¶¡:2023/1/9 ¤U¤È 03:03:24) ´£¨ì¦Ü¤Ö¶}¤GÓX400¤H¡A¦Xp800¤H¡Cx16¶gªvÀø¡C ¥t¥~¥i¯à°l¥[¡ã16¡ã52¶gªº©µ¦ùªvÀøÁ{§É¡C ¤Î¥t°µ¤@ÓTCSªº¤T´ÁÁ{§É¡A¬ù250¤H¡C ºÃ°Ý¡G ¨È·à±d³]pªº¤T´ÁÁ{§É¸ÕÅçpµe¡A¨äµ²ªG¡A§ñÃö¤§«áÃÄÃҥӽСA¾¯¶q¡B¦¨¥»µ¥¬Òn¦Ò¶q¡C ¨È·à±dªº¤T´ÁÁ{§É¸ÕÅçpµe¬O¤§«á¨ÖÁÊÃÄ°Ónªº¶Ü¡H À³¸Ó¬OÃÄ°Ó¨ÖÁʨȷà±d«á¡A¥ÑÃÄ°Ó´£¥X¥¦¦Û¤vªº¤T´ÁÁ{§É¸ÕÅçpµe¤~¦X²z¡C
2.¦p¤Ñ©R¤j¤j©Òz(10141925 µoªí®É¶¡:2023/1/9 ¤U¤È 05:10:41) ¡K¡K¤½¥¬4»õ¬ü¤¸¥H¤Wªº¶Ò¸êp¹º¡K¡K ºÃ°Ý¡G YÃÄ°Óìq60»õ¬üª÷¨Ö¨È·à±d(§tÃÄ°Ó¦Û¿ì¤T´Á¸êª÷)¡A ¤§«áÃÄ°Óµo²{¨È·à±d¶¶§Q¶Ò±o4»õ¬ü¤¸¸êª÷¡A ÃÄ°Ó¬O§_¦Û¦æ¦©°£4»õ¬ü¤¸¡A¦Ó¤½§i¥H56»õ¨Ö¨È·à±d¡A ¦³§C¦ô¨ÖÁÊ»ù¶ûºÃ¡H
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/1/10 ¤W¤È 10:09:27
²Ä 5873 ½g¦^À³
|
Dupilumab(Dupixent) 2017/03º§å¯SÀ³©Ê¥Öª¢¤W¥«¥H¨Ó,¤wÀòFDA §åã¤W¥«, ²Öp5ºØ¾AÀ³¯g (¯SÀ³©Ê¥Öª¢¡Bý³Ý¡BºC©Ê»óÄuª¢¦ñ»ó®§¦×¡B¶Ý»Ä©Ê²É²ÓM©Ê¹ºÞª¢¡Bµ²¸`©ÊÄo¯l) µ¥. ¨ä¥LÁÙ¦³¼ÆÓ¾AÀ³¯g¥¿¦bÁ{§É¤¤,¦pCOPD...
2022¦~«e3©u²Öp¾P62»õ¬ü¤¸,¬ü°Ï¦û75%,¥þ¦~¾P°â¬ù85»õ¬ü¤¸ ¦ô2015~2016¦~¹F³Ì°ª¾P°â130»õ¼Ú¤¸(140»õ¬ü¤¸.)
FDA§åã¾ú¥v FDA §åã¡G¬O¡]2017 ¦~ 3 ¤ë 28 ¤éº¦¸§åã¡^ «~µP¦WºÙ¡GDupixent ³q¥Î¦WºÙ¡Gdupilumab ¾¯«¬¡Gª`®g¾¯ ¤½¥q¡GRegeneron Pharmaceuticals, Inc. ªvÀø¡G¯SÀ³©Ê¥Öª¢¡Bý³Ý¡BºC©Ê»óÄuª¢¦ñ»ó®§¦×¡B¶Ý»Ä©Ê²É²ÓM©Ê¹ºÞª¢¡Bµ²¸`©ÊÄo¯l Dupixent (dupilumab) ¬O¤@ºØ¥Õ²ÓM¤¶¯À 4 ¨üÅé £\ «ú§Ü¾¯¡A¥Î©óªvÀø¯SÀ³©Ê¥Öª¢¡Bý³Ý¡BºC©Ê»óÄuª¢¦ñ»ó®§¦×¯f¡B¶Ý»Ä©Ê²É²ÓM©Ê¹ºÞª¢©Mµ²¸`©ÊÄo¯l¡C
Dupixent ¾A¥Î©óªvÀø¡G 1.¯SÀ³©Ê¥Öª¢¡X¡X¥Î©óªvÀø 6 Ó¤ë¤Î¥H¤W±w¦³¤¤«×¦Ü««×¯SÀ³©Ê¥Öª¢ªº¦¨¤H©M¨àµ£±wªÌ¡A³o¨Ç±wªÌªº¯e¯f¤£¯à³q¹L§½³¡³B¤èÀøªk±o¨ì¥R¤À±±¨î¡A©ÎªÌ·í³o¨ÇÀøªk¤£¥i¨ú®É¡C Dupixent ¥i»P©Î¤£»P§½³¡¥Ö½èÃþ©T¾J¤@°_¨Ï¥Î¡C ý³Ý¡X¡X§@¬° 6 ·³¤Î¥H¤W±w¦³¥H¶Ý»Ä©Ê²É²ÓMªí«¬¬°¯S¼xªº¤¤«×¦Ü««×ý³Ý©Î¤fªA¥Ö½èÃþ©T¾J¨Ì¿à©Êý³Ýªº¦¨¤H©M¨àµ£±wªÌªºªþ¥[ºû«ùªvÀø¡C 2.ºC©Ê»óÄuª¢¦ñ»ó®§¦×¯f¡X¡X§@¬°ºC©Ê»óÄuª¢¦ñ»ó®§¦×¯f (CRSwNP) ±±¨î¤£¨Îªº¦¨¦~±wªÌªºªþ¥[ºû«ùªvÀø¡C ¶Ý»Ä©Ê²É²ÓM©Ê¹ºÞª¢¡X¡X¥Î©óªvÀø±w¦³¶Ý»Ä©Ê²É²ÓM©Ê¹ºÞª¢ (EoE) ªº 12 ·³¤Î¥H¤W¡BÅé«¦Ü¤Ö 40 ¤½¤çªº¦¨¤H©M¨àµ£±wªÌ¡C 3.µ²¸`©ÊÄo¯l - ¥Î©óªvÀø±w¦³µ²¸`©ÊÄo¯l (PN) ªº¦¨¦~±wªÌ¡C
FDA History Dupixent Print Save Dupixent FDA Approval History Last updated by Judith Stewart, BPharm on Oct 2, 2022.
FDA Approved: Yes (First approved March 28, 2017) Brand name: Dupixent Generic name: dupilumab Dosage form: Injection Company: Regeneron Pharmaceuticals, Inc. Treatment for: Atopic Dermatitis, Asthma, Chronic Rhinosinusitis with Nasal Polyps, Eosinophilic Esophagitis, Prurigo Nodularis Dupixent (dupilumab) is an interleukin-4 receptor alpha antagonist used for the treatment of atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis, and prurigo nodularis.
Dupixent is indicated for the treatment of: Atopic Dermatitis - for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Dupixent can be used with or without topical corticosteroids. Asthma - as an add-on maintenance treatment of adult and pediatric patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma. Chronic Rhinosinusitis with Nasal Polyposis - as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP). Eosinophilic Esophagitis - for the treatment of adult and pediatric patients aged 12 years and older, weighing at least 40 kg, with eosinophilic esophagitis (EoE). Prurigo Nodularis - for the treatment of adult patients with prurigo nodularis (PN). |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/1/10 ¤W¤È 08:42:14
²Ä 5872 ½g¦^À³
|
investor.regeneron.com/static-files/5f682777-4984-400b-bacb-3041044bb4b6
Dupilumab ³Ì·s¬ã¨sµo®i¤Î¤W¥«¦¨ªG ³ø§i:2023/01/09
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/1/9 ¤U¤È 05:10:41
²Ä 5871 ½g¦^À³
|
¤¸¤ë31¤éªÑªF·| 2¤ë¤¤/¤U¦¯¡B¦ôp¥ý¸Ñª¼ ¤½¥¬4»õ¬ü¤¸¥H¤Wªº¶Ò¸êp¹º 3¤ë©³¨p¶Ò 4¤ëªì¤½§G¸Ñª¼µ²ªG¡B¨Ã¥]¾P¨é°Ó ¼Ú¦{区°Ó·~¤Æ±ÂÅv¡D
¥H¤WÓ¤H²q´ú! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/1/9 ¤U¤È 03:03:24
²Ä 5870 ½g¦^À³
|
2¦~«eªºASLN¶Ò¸ê¾ú¥v¡G ir.aslanpharma.com/financial-information/sec-filings
2021/01/29 ¤½§G 1»õ5¤d¸U¬ü¤¸ªº¶Ò¸êp¹º¡]·í¤éASLNªÑ»ù ADR 2.22¬ü¤¸ 2021/02/24 ¤½§G ¨p¶Ò1800¸U¬ü¤¸¡A3.52¬ü¤¸¡þ¨CªÑADR¡]¹j¤é¦¬½L4¡P46¡A½L¤¤5¡P49¬ü¤¸¡^
2021/03/01 ¤½§G ASLAN001 1b 24¤H¡A´Á¤¤³ø§i¡]·í¤é³Ì°ª6.75¬ü¤¸⋯¡A¦¬5¡P25¬ü¤¸⋯¶Ò¸ê´Á¶¡³Ì°ª»ù¡AÃz¤Ñ¶q52¡P35 ¦Ê¸UªÑADR¡A¦¨¥æª÷ÃB¬ù2¡D7»õ¬ü¤¸¥H¤W¡C 2021//03/04 ¤½¥¬ ¥]销 4¬ü¤¸/¨CªÑ4¬ü¤¸¡C ¤@¤@¤@¤@¤@¤@¤@¤@¤@
¦pªG2b 300¤Hx16¶g¸Ñª¼²Å¦X¹w´Á¡AĹ¹LLebrikizumab 2b Àø®Ä 20%¡]¦©°£¹ï·Ó²Õ¡^
2023¦~Q2 ¡A¥²¶·¶Ò¶°¤T´ÁADÁ{§É¸êª÷¡A¦ô4»õ¬ü¤¸¥H¤W ¡A¬°¤W¤@¦¸2021¦~Q1©Ò¶Òªº4¿¡C ¥t¶·¼Ú¬w°Ïªº°Ó·~¤Æ±ÂÅv¡C
¥H°µ¬° ¤T´ÁADÁ{§É¸êª÷¡G
¦Ü¤Ö¶}¤GÓX400¤H¡A¦Xp800¤H¡Cx16¶gªvÀø¡C
¥t¥~¥i¯à°l¥[¡ã16¡ã52¶gªº©µ¦ùªvÀøÁ{§É¡C
¤Î¥t°µ¤@Ó¤QTCSªº¤T´ÁÁ{§É¡A¬ù250¤H¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/1/8 ¤U¤È 04:54:34
²Ä 5869 ½g¦^À³
|
2b EASI75´Á±æȦôp¡G ¨ÌASLAN004 1b mITT EASI75=11/16=69%
¨ä¤¤ì¥»«D¶Ç²ÎAD6¦ì¡A°ò缐EASI19ªº»´¯g¡A8¶gªvÀø«á0¦ì¦ì¹FEASI75¡C¡]mITT¤w±Æ°£¡^
Y¨Ì¶Ç²ÎADªvÀø¡]Y1b¿z¿ïÄY®æ±Æ°£«D¶Ç²ÎAD¡^
¦Ü¤Ö5/6¡ã6/6·|¹FEASI75
«hEASI75±N¦^Âk (11¤Q5)/(16+6)=73% (11+6)/(16+6)=77%
¥t¥~¤¤Â_²v3/16=19%
¨Ì¾Ú¤T´Á¤¤Â_²v¶È7%¡ã8% EASI75¡]11+6¡^/¡]16+6-1¡^=81%
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/1/8 ¤U¤È 04:30:47
²Ä 5868 ½g¦^À³
|
¥²n±ø¥ó :ASLAN004 2B ¸Ñª¼±ø¥ó¹F¦p¤U: EASI75 69% VS 24%(¹ï·Ó²Õ),®t²§45% IGA0,1 53% VS 15%(¹ï·Ó²Õ),®t²§38%
ASLAN004 2b ¸Ñª¼´Á±æÈ ----------------------------------- Eblasakimab improves multiple disease measures in adult patients with moderate-to-severe atopic dermatitis in a randomized, double-blinded, placebo-controlled, Phase 1 study aslanpharma.com/wp-content/uploads/2022/09/EADV-Efficacy-Outcomes-poster_FINAL-1.1.pdf
Lenrikizumab phs3 : www.almirall.com/documents/portlet_file_entry/4257831/300322_ORI+Lebri+pres+ENG+%2B+pres+vf.pdf/5ad7034f-0dd9-492f-eb83-1515071417de
Lenrikizumab 2b : jamanetwork.com/journals/jamadermatology/fullarticle/2761466
(1)ASLAN004 1b mITT*8 ¶gªvÀø ²Ä8¶gASLAN004, EASI75 69% VS 15%(¹ï·Ó²Õ),®t²§54%------ ²Ä16¶gASLAN004, EASI75 69%~81% VS 24%(¹ï·Ó²Õ),®t²§45%~57%------(¦ôp)
VS Lenrikizumab phs2 *8/16 ¶gªvÀø ²Ä8¶gLenr., EASI75 45% VS 18%(¹ï·Ó²Õ),®t²§27%------(¥Øµø§P¹Ï) ²Ä16¶gLenr.,EASI75 60.6% VS 24.3%(¹ï·Ó²Õ),®t²§36.3%------
(2)ASLAN004 1b mITT*8 ¶gªvÀø ²Ä8¶gIGA0,1 44% VS 15%(¹ï·Ó²Õ),®t²§29%------ ²Ä16¶gIGA0,1 53%~65% VS 15%(¹ï·Ó²Õ),®t²§38%~50%-----(¨Ì¾Úlebrikizumab ©Ò±À¦ô²Ä16¶g,EASI75-IGA0,1¤§¶¡ ®t²§16%)
VS Lenrikizumab phs2 *8/16 ¶gªvÀø ²Ä8¶gLenr., IGA0,1 30% VS 5%(¹ï·Ó²Õ),®t²§25%------(¥Øµø§P¹Ï) ²Ä16¶gLenr.,IGA0,1 44.6% VS 15.3%(¹ï·Ó²Õ),®t²§29.3%------
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³v®ö«È10146323 |
µoªí®É¶¡:2023/1/8 ¤U¤È 04:12:28
²Ä 5867 ½g¦^À³
|
³o¼Ë°Ý¡A¤]³\¤Ñ©R¤j¤]«ÜÃø¦^µª¡A Á`¤§¡A§Æ±æ¹F¼Ð¡A¤j®a³£ÁÈ¿ú¡I |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³v®ö«È10146323 |
µoªí®É¶¡:2023/1/8 ¤U¤È 03:16:44
²Ä 5866 ½g¦^À³
|
33¬ü¤¸¡ã¯u¬O®¶¾Ä¤H¤ß¡I
¦ý¥²n±ø¥óªº¹F¦¨¡A¾÷²v¤j¤£¤j¡H |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/1/8 ¤U¤È 01:08:13
²Ä 5865 ½g¦^À³
|
©êºp½Ð§Ñ°O¤W¤@½g¤å³¹¡G
ASLN³Q¨ÖÁÊ»ùȦôºâ :×¥¿¤@
¨Ì¾Ú Lebrikizumabªº¤½¥qDERM. AD 2bÁ{§É°µ§¹, 11»õ¬ü¤¸,2019¦~©³³QLily¨ÖÁÊ.(ý³Ý/COPD¤T´Á¥¢±Ñ),¥Ø«e»ùÈ11*140/50=31»õ¬ü¤¸
2019¦~©³·í®Édupilmab ¥«³õ»{¦P³Ì°ª¾P°â50»õ¬ü¤¸. 2019¦~dupilumab ¾P°â23»õ¬ü¤¸. 2022¦~«e¤T©u¤w¾P 61»õ¬ü¤¸,¥þ¦~Á`¾P±Nªñ85»õ. REGN¤½¥q©Ò¦ôdupilumab ³Ì°ª¾P°â130»õ¼Ú¤¸(140»õ¬ü¤¸)¦b2024¦~¥i¹F¦¨.
31»õ¬ü¤¸ AD¦û55% «¬IIª¢¯g. 31/0.55=56»õ¬ü¤¸---«¬IIª¢¯g
31+25*0.6=46»õ¬ü¤¸-------¦ô²{ª÷¨ÖÁÊ»ù(¨ÖÁʪ̥²¶·¤ä¥I¤W´åCSL¶O¥Î)
°²¦p¥»¦¸2023/Q2¼W¸ê§¹¦¨ªÑ¥»¥Ñ7¸UªÑ¼W¥[¨ì15.14ªÑADR. ¶Ò¸ê4»õ¬ü¤¸¡A¥t¥[¼Ú°Ï±ÂÅv¡C
¦~©³¤½¥q²bÈ4»õ¬ü¤¸¤Q¤Wz46»õ¬ü¤¸¡×50»õ¬ü¤¸⋯³Q¨ÖÁÊ»ù
50»õ¬ü¤¸/15.14¸U¤dªÑADR=33 ¬ü¤¸/ªÑADR. -----
¥²n±ø¥ó :ASLAN004 2B ¸Ñª¼±ø¥ó¹F¦p¤U: EASI75 69% VS 24%(¹ï·Ó²Õ),®t²§45% IGA0,1 53% VS 15%(¹ï·Ó²Õ),®t²§38%
**Lebrikizumab 2b EASI75 61% VS 24%(¹ï·Ó²Õ),®t²§37% IGA0,1 45% VS 15%(¹ï·Ó²Õ),®t²§30%
***ASLAN004 2b¹w´Á VSLebrikizumab 2b(¦©°£¹ï·Ó²Õ)
EASI75 45% VS 37%=121% IGA0,1 38% VS 30%=126% |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/1/8 ¤U¤È 12:16:37
²Ä 5864 ½g¦^À³
|
DERM¤½¥q³Q¨ÖÁÊ11»õ¬ü¤¸¤§¦ôºâ¶·¥[¦^ 2.8»õ¬ü¤¸ªº¥iÂà´«¤½¥q¶Å =13.8»õ¬ü¤¸ =Lebrikizumab 20»õ¬ü¤¸³Ì°ª销°âªº§é²{È¡D
©Ò¥HASLAN004³Q¨ÖÁÊÈ =13.8x140/50 =38.64.....AD»ùÈ¡KA
(38.64/55%-38.64)x0.6 =18.9....¨ä¥L¾AÀ³¯g»ùÈ...B
A+B=56»õ¬ü¤¸¡K ASLN¿W±o
¨ÖÁȪ̥t¶·¤ä¥ICSLªºÅv§Q¶O¥Î¡D
°²³] 欧°ÏASLAN004¡B2b¸Ñª¼«á¦³±ÂÅv
¦~©³¸êª÷¦³4»õ¬ü¤¸¡D
¥»¦¸¶Ò¸ê©Îµo¥iÂà´«¤½¥q¶Å¥un¶Ò¶°4»õ¬ü¤¸
4»õ¬ü¤¸/5.6¬ü¤¸-ªÑ =7.14¸U¤dªÑADR
ªÑ¥»=7+7.14+1(¤º³¡»{ªÑ) =15.14¸U¤dªÑ
56»õ¬ü¤¸(³Q¨ÖÁʪ÷额)/15=14¸U¤dªÑ =37¬ü¤¸/ªÑ¡K
«e´£¡G2b¸Ñª¼¼Æ¾ÚÀu©óLebrikizumab 2b Àø®Ä20%.
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/1/8 ¤W¤È 11:40:54
²Ä 5863 ½g¦^À³
|
2020/01/10Dermira,Inc.¤½§i³QLily¨ÖÁÊ11»õ¬ü¤¸ 18.75¬ü¤¸/ªÑ
2019/02Lebrikiumab AD ¸Ñª¼¦¨¥\ 2019/02欧°Ï±ÂÅv§¹¦¨ 2019/02 ¥«³õ¶Ò¸ê1.3»õ¬ü¤¸(¨CªÑ13.25¬ü¤¸)
2019/Q3(2019/11/05/¤½¥¬) Dermira, Inc.°]³ø
www.sec.gov/Archives/edgar/data/1557883/000119312519284714/d816988dex991.htm
Àç¹B²{ª÷¡G3.538»õ¬ü¤¸ ªø´Át¶Å¡G0.718»õ¬ü¤¸ ¥iÂà´«¤½¥q¶Å¡G2.826»õ¬ü¤¸ ªÑªFÅv¯q(¤½¥q²bÈ)¡G0.144»õ¬ü¤¸
Selected Consolidated Balance Sheet Data
(in thousands)
September 30, 2019 December 31, 2018
Cash and investments
$ 360,163 $ 316,002 Working capital
353,881 296,853 Total assets
436,241 344,321 Term Loan
71,808 32,566 Convertible notes, net
282,607 281,223 Accumulated deficit
(885,453 ) (745,038 ) Total stockholders¡¦ equity (deficit)
14,480 (9,039 |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/1/7 ¤W¤È 10:06:33
²Ä 5862 ½g¦^À³
|
CNTB CBP-201ªº2b ADÀø®Ä¡BµLªkÀò¥«³õ»{¦P¡B¶Ò¤£¨ìp¹ºªº2.5»õ¬ü¤¸¸êª÷¡D
¥Ø«e¥«È¤£¨ì5¤d¸U¬ü¤¸¡D |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2023/1/7 ¤W¤È 10:03:17
²Ä 5861 ½g¦^À³
|
¦pªG¶Ò¸ê¯à¦¨¥\¡AªÑ»ù·|º¦¤@¤jªi ¦ý®³¤°»ò¥X¨ÓÅý¤HÄ@·N¥X¿ú ¤£´N¬O¨}¦nªº¼Æ¾Ú¶Ü? ÁÙ¬O¨ä¹ê¥L̤w¸g³£ª¾¹D¤F ©Ò¥H¡A¶Ò¸ê¦¨¥\»P§_´N¬OÃöÁä ¥[ªo |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/1/7 ¤W¤È 09:56:01
²Ä 5860 ½g¦^À³
|
ASLN¦A¨ÓnÄÀ¥Xªº¬O12¸U¤dªÑADR¡B ¬O¤wµo¦æ7¸U¤dªÑADR ªº12/7=171%
¬O»Ýn½T¹êªºÀø®Ä°µ¬°¨Ì¾Ú¡D EASI75/IGA0,1 Àø®ÄÀu©óLebrikizumab 2b 20%¥H¤W¡B ¥«³õ¤j¤á¤~·|¶R³æ¡D
¥Ø«e¥«È¤£¨ì5¤d¸U¬ü¤¸¡Bn¶Ò6»õ6¸U¬ü¤¸ ¬O«D±`¤§¤j¨Æ¡D |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2023/1/7 ¤W¤È 09:12:22
²Ä 5859 ½g¦^À³
|
ÁÂÁ¤ѩR¤jªº¤ÀªR¡A¦ý¥H1B 1b mITT*8¶gªºµ²ªG±Àºt¡A¦b¤wÄY®æ±±ºÞ¦¬®×«~½èªº«e´£¤U¡A2B¼Æ¾Ú¦³Àu©ó§ù¥²ª¢¾÷²v¬O¦s¦bªº¡A¬G¤½¥q¤]¤£¥²©ë©ó¤¤¤@««×AD³æ§Ü2bÁ{§É¬ã¨sµL´Á¤¤¼Æ¾Ú³ø§i¤@»¡¡A¤@¤Á¤´¥H²Ö¿nªº¥¿¦V¼Æ¾Ú¬°Àu¥ý¡A¦³¥¿¦V´Á¤¤¼Æ¾Ú¥i°Ñ¦Ò¡A¤jÃļt©Î¾÷ºc§ó·|¶i³õ¾ß«K©y~ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/1/7 ¤W¤È 06:25:22
²Ä 5858 ½g¦^À³
|
¾Ú²Îp´Á¤¤³ø§i¼vÅT¤F³Ì²×³ø§i5%~10%ªº·Ç½T©Ê¡D
¦p´Á¤¤³ø§i¦³¦nªºÀø®Ä¡B°Ñ»PªÌ·|»{¯uªº°µ§¹¡D
¦p´Á¤¤³ø§i¤£¨Î¡B°Ñ»PªÌ¤¤Â_²v·|¼W¥[¡D
¥Ø«e¤¤¤@««×AD³æ§Ü2bÁ{§É¬ã¨s¥¼¨£¦³¥ô¦ó´Á¤¤¸Ñª¼³ø§i¡D |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/1/7 ¤W¤È 05:58:35
²Ä 5857 ½g¦^À³
|
2021/Q1 ¥Î1b´Á¤¤³ø§i24¤H¸ê¬ìx8¶gªvÀø¡B¶Ò¸ê¬ù¤@»õ¬ü¤¸
2023¦~Q2©Ò¶Ò´Á±æÈ6»õ¬ü¤¸ ¦pµL300¤Hx16¶gªºªvÀøÀu¶VÀø®Ä¼Æ¾Ú¡BÃø±q¥«³õªº¤j«È¤á¤f³U¤¤®³¤j¿ú,
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2023/1/6 ¤U¤È 11:25:02
²Ä 5856 ½g¦^À³
|
Yn¿v¹Ú½ñ¹ê¡A´NnºÉ¦¤½§G¥¿¦V´Á¤¤¼Æ¾Ú¡A³o¼Ë¤~¯à¦b´Á¤¤¤½§G¦Ü¸Ñª¼¼Æ¾Ú¤¤¶¡¡A¹F¨ì³Ì¤jªº®Ä¯q~ªü·à¥[ªo
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/1/6 ¤U¤È 08:52:42
²Ä 5855 ½g¦^À³
|
¤½¥q¸g¹L200mg/ml°ª¿@«×aslan004°w¾¯ªº¬ãµo(¤§«e100mg/ml),¥i¸`¬Ù50%¦¨¥». ¨C°w¥i¥´400mg/2ml.
°ê»Ú§ÜÅé°w¾¯ªº¥N¤u»ù¬O¨ÌÃĪº«¶qp»ù : ¬ü¤¸/¤½§J. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/1/6 ¤U¤È 08:38:35
²Ä 5854 ½g¦^À³
|
¤µ¤Ñ¤~¬Ý³q¤½¥q²³øp.31/p.32, ¤Î Á{§É¹êÅç/clinicaltrials.gov ºô¤¤ªº¤å¦r
¦p¦¹¥i¥[±j«e¤G/¤T°wªº600Mmg ªºÀø®Ä½T«O:
ASLAN004 2b¤@½u Q2W«e0/1¶g¬Ò¥´600mg.¨ä¥LW2~W14,¨C¤G¶g¤À§O¥´300mg/400mg Q4W«e0/1/2¶g¬Ò¥´600mg.¨ä¥LW6/W10/W14,¨C¥|¶g¤À§O¥´400mg/600mg
------------------------------ ASLAN004 2b¤G½u QW«e0/1¶g¬Ò¥´600mg.¨ä¥L¨C¶g¥´400mg
clinicaltrials.gov/ct2/show/NCT05158023
Experimental: ASLAN004 300 mg q2w
ASLAN004 300 mg q2w - loading doses at Baseline and Week 1(²Ä0/1¶g¦U¥´600mg,), followed by regular doses of 300mg q2w from Week 2 to Week 14(²Ä2~14¶g¦U¥´300mg,).
ir.aslanpharma.com/static-files/1c525489-d209-42c4-af7e-992f23c4251c 2023/01/06 ¤½¥q²³øp.31/p.32
300mg Q2W W0/W1:600mg:Q2W (w2~w14):300mg ¦@9°w,¦Xp3300mg (²Ä0/1¶g¦U¥´600mg, ²Ä2~14¶g:¨C¤G¶g¥´¤@°w300mg)
400mg Q2W W0/W1:600mg/Q2W (w2~w14):400mg ¦@9°w,¦Xp4000mg (²Ä0/1¶g¦U¥´600mg, ²Ä2~14¶g:¨C¤G¶g¥´¤@°w400mg)
400mg Q4W W0/W1/W2:600mg/Q4W (w6~w14):400mg ¦@6°w,¦Xp3000mg (²Ä0/1/2¶g¦U¥´600mg, ²Ä6/10/14¶g:¨C¥|¶g¥´¤@°w400mg)
600mg Q4W W0/w1/W2:600mg/Q4W (w6~w14):600mg ¦@6°w,¦Xp3600mg (²Ä0/1/2¶g¦U¥´600mg, ²Ä6/10/14¶g:¨C¥|¶g¥´¤@°w600mg)
p.31 TREK-AD: Phase 2b in biologic naïve patients •Loading dose of 600mg for the Q2W dose groups at week 1(w0) and week 2(week 1) •Loading dose of 600mg for the Q4W dose groups at week 1(w0), week 2(w 1) and week 3(w 2)
400mg QW(¨C¶g¤@°w) W0/W1:600mg/w2~w15:400mg ¦@16°w,¦Xp6800mg (²Ä0/1¶g¦U¥´600mg, ²Ä2~15¶g:¨C¶g¥´¤@°w400mg) Loading dose of 600mg at week 1(w0) and week 2(w 1)
p.32 TREK-DX: Phase 2 study in dupilumab experienced patients Topline data expected 1Q 2024
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/1/6 ¤U¤È 04:42:40
²Ä 5853 ½g¦^À³
|
°ê»Ú¤W¨ú±oÃĵýªº·sÃÄ»ùÈ¡G ¦y®p¾P°â额x3¿
¦p¡A¦ô¦y®p¾P°â=10»õ¬ü¤¸¡C
¥«³õ³Q¨ÖÁÊ»ùÈ=10x3=30»õ¬ü¤¸¡C
Lebrikizumab ·íªì³Q¨Ö®ÉÂù¤è¤½¥q»{¦P ¦y®p销°â¬°20»õ¬ü¤¸(15+欧°Ï5)¡B §é²{È11»õ¬ü¤¸¨ÖÁʤ§¡D(AD¤T´Á¶}©lªº¤TÓ¤ë)
Lily¥t¥²¶·¤ä¥IDERM¤½¥q¤W´å±ÂÅv¤½¥qROCHEªñ12»õ¬ü¤¸ªºÃ±¬ùª÷+10%销°â¤À¼í¡D
ASLAN004 AD¥«³õ¨ÌLebrikizumab¦ô20x140/50=56»õ¬ü¤¸³Ì°ª¾P°â
56/55%=100»õ¬ü¤¸ªº«¬II ª¢¯g¥«³õ¡D
Y¥þ³¡¨ú±oÃįg¥i¾Ö¦³300»õ¬ü¤¸¥«È (¥H¤WASLN+CSL¦Xp»ùÈ) |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/1/6 ¤U¤È 04:16:56
²Ä 5852 ½g¦^À³
|
ASLN 46»õ¬ü¤¸+ CSL 7.5»õ¬ü¤¸(«eª÷+ùµ{ª÷)+10%销°â¤À¼í
¦Xpµ´¹ï¶W¹L60»õ¬ü¤¸
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/1/6 ¤U¤È 01:23:56
²Ä 5851 ½g¦^À³
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2023/1/6 ¤U¤È 12:14:15
²Ä 5850 ½g¦^À³
|
¬ü°ê¥Í§Þ¤½¥q Arena Pharmaceuticals(ÁÙ¨S®³¨ìÃÄÃÒ) (110.12.14¤½§i³Q½÷·ç¨ÖÁÊ¡B111.03.30¤T´Á¸Ñª¼¦¨¥\) ªÑ¥»¡G67,000,000ªÑ ¼ìºÅ©Êµ²¸zª¢¬O¤@ºØ¼vÅT¬ü°ê300¸U¤HªººC©Êª¢Äp©Ê¸z¯f ³Ì°ª¾P°âÃB¥i¹F 25»õ¬ü¤¸ Etrasimod ¥¿³B©ó«á´Áªº¬ã¨s¶¥¬q¡AªvÀø®ÄªG±N¤ñ Bristol Myers Squibb(BMY-US) (¦Ê®É¬ü¬I¶QÄ_)ÃļtºX¤Uªº Zeposia §ó¦³®Ä ½÷·ç¦P·N¥H 67»õ¬ü¤¸¦¬ÁÊ¡A´«ºâ¨CªÑ¦¬Áʳø»ù¬° 100 ¬ü¤¸
¬ü°ê¥Í§Þ¤½¥qTurning Point Therapeutics, Inc. (ÁÙ¨S®³¨ìÃÄÃÒ) (111.06.04¤½§i³Q¥²ªv§´¬I¶QÄ_¨ÖÁÊ¡B³Q¨Ö·í¤U¬°¤G´ÁÁ{§É¸ÕÅ礤) ªÑ¥»¡G53,947,368ªÑ ªÍÀù¬°¥þ²y²Ä¤G¤jÀù¯g¡A2022¦~¦ô¥þ²y±wªÌ¦ô¬°250¸U¤H¡C ³Ì°ª¾P°âÃB¥i¹F 10»õ¬ü¤¸ ¸ÓÃÄ¥¿³B©ó2bÁ{§Éªº¬ã¨s¶¥¬q¡ATurning Point¤â¤¤´¤¦³¥i¯à¤ñÄvª§¹ï¤â½÷·ç¡]Pfizer¡^©Mù¤ó¡]Roche¡^§ó¨ãÀu¶Õªº«D¤p²ÓMªÍÀù (NSCLC)ªvÀøÃĪ«¡C ¬I¶QÄ_¦P·N¥H41»õ¬ü¤¸¦¬ÁÊ¡A´«ºâ¨CªÑ¦¬Áʳø»ù¬° 76 ¬ü¤¸
·s¥[©Y¥Í§Þ¤½¥q ASLAN Pharmaceuticals(ÁÙ¨S®³¨ìÃÄÃÒ) ªÑ¥»¡G69,663,404ªÑ ²§¦ì©Ê¥Ö½§ª¢¬O¤@ºØ¼vÅT¬ü°ê2,400¸U¤H(¥þ²y¶W¹L2»õ)ªººC©Êª¢¯g ³Ì°ª¾P°âÃB¥i¹F 140»õ¬ü¤¸(§ùÁת¢) 004¥¿³B©ó2bÁ{§Éªº¬ã¨s¶¥¬q¡AªvÀø®ÄªG±N¤ñÁÉ¿ÕµáÃļtºX¤Uªº§ùÁת¢§ó¦³®Ä XXX¦P·N¥H 000»õ¬ü¤¸¦¬ÁÊ¡A´«ºâ¨CªÑ¦¬Áʳø»ù¬°???¬ü¤¸ ------------------------------------------------------------------------------------------------------------------------------------ «ö·Ó¥þ²y¯f±w¤H¼Æ¡B³Ì°ª¾P°âÃB¡BªvÀø®ÄªG³Ì¦nµ¥µ¥±À¦ô ¦¬Áʨȷà±d»ù®æÀ³¸Ó°ª©ó00»õ¬ü¤¸¡C
¨Ì¤Ñ©R¤j¤j10141925 µoªí®É¶¡:2023/1/6 ¤W¤È 08:42:41µoªí 31»õ¬ü¤¸ AD¦û55% «¬IIª¢¯g. 31/0.55=56»õ¬ü¤¸---«¬IIª¢¯g
31+25*0.6=46»õ¬ü¤¸-------¦ô²{ª÷¨ÖÁÊ»ù(¨ÖÁʪ̥²¶·¤ä¥I¤W´åCSL¶O¥Î)
46»õ¬ü¤¸À³¬O§C¦ôÈ.
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/1/6 ¤W¤È 08:42:41
²Ä 5849 ½g¦^À³
|
ASLN³Q¨ÖÁÊ»ùȦôºâ :
¨Ì¾Ú Lebrikizumabªº¤½¥qDERM. AD 2bÁ{§É°µ§¹, 11»õ¬ü¤¸,2019¦~©³³QLily¨ÖÁÊ.(ý³Ý/COPD¤T´Á¥¢±Ñ),¥Ø«e»ùÈ11*140/50=31»õ¬ü¤¸
2019¦~©³·í®Édupilmab ¥«³õ»{¦P³Ì°ª¾P°â50»õ¬ü¤¸. 2019¦~dupilumab ¾P°â23»õ¬ü¤¸. 2022¦~«e¤T©u¤w¾P 61»õ¬ü¤¸,¥þ¦~Á`¾P±Nªñ85»õ. REGN¤½¥q©Ò¦ôdupilumab ³Ì°ª¾P°â130»õ¼Ú¤¸(140»õ¬ü¤¸)¦b2024¦~¥i¹F¦¨.
31»õ¬ü¤¸ AD¦û55% «¬IIª¢¯g. 31/0.55=56»õ¬ü¤¸---«¬IIª¢¯g
31+25*0.6=46»õ¬ü¤¸-------¦ô²{ª÷¨ÖÁÊ»ù(¨ÖÁʪ̥²¶·¤ä¥I¤W´åCSL¶O¥Î)
°²¦p¥»¦¸2023/Q2¼W¸ê§¹¦¨ªÑ¥»¥Ñ7¸UªÑ¼W¥[¨ì20¸UªÑADR.
46»õ¬ü¤¸/20¸UªÑADR=23 ¬ü¤¸/ªÑADR. -----¥²»ù±ø¥ó :ASLAN004 2B ¸Ñª¼±ø¥ó¹F¦p¤U: EASI75 69% VS 24%(¹ï·Ó²Õ),®t²§45% IGA0,1 53% VS 15%(¹ï·Ó²Õ),®t²§38%
**Lebrikizumab 2b EASI75 61% VS 24%(¹ï·Ó²Õ),®t²§37% IGA0,1 45% VS 15%(¹ï·Ó²Õ),®t²§30%
***ASLAN004 2b¹w´Á VSLebrikizumab 2b(¦©°£¹ï·Ó²Õ)
EASI75 45% VS 37%=121% IGA0,1 38% VS 30%=126% |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GPica10150664 |
µoªí®É¶¡:2023/1/5 ¤U¤È 10:33:21
²Ä 5848 ½g¦^À³
|
¥ý¹L1¤¸§a¡A0.x¤¸¬Ý¤F³£¨S«H¤ß¤F¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2023/1/5 ¤U¤È 10:10:03
²Ä 5847 ½g¦^À³
|
§Ú¤ñ¸û«È®ð ¨È·à±d¥ý©Ô¹L1¬ü¤¸µ¹·à¤Í«H¤ß¦A»¡ ¥[ªo°Ú¡A¨È·à±d2023°fÂà³Ó |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/1/5 ¤U¤È 05:43:58
²Ä 5846 ½g¦^À³
|
CNTB 2b¸Ñª¼«e·|©Ô¨ì28¶ô¬ü¤¸¡A¥Lªº2bý³Ý¤w¶}©l¡A¥i¯à¤]¬Oì¦]¤§¤@¡C
¤£n¤p¬ÝASLAN004 2bÁ{§Éªº»ùÈ¡I¥LÁÙ¦³ý³Ý¡BEOE⋯¨ä¥L¾AÀ³¯g¡C
Lebrikizumab «h¬Oý³Ý¡C¤ÎCOPD ¤T´ÁÁ{§É¬Ò¤w¥¢±Ñ¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³v®ö«È10146323 |
µoªí®É¶¡:2023/1/5 ¤U¤È 05:33:47
²Ä 5845 ½g¦^À³
|
¦³·N«ä¡I CNTB 2021/08/10 ¦¬½L»ù28.5¬ü¤¸ ¬Q¤é¦¬½L0.859 Asln¡A¤µ¤é·|¤£·|Ä~Äò¥û²rºt¥X¡H |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/1/5 ¤U¤È 04:32:12
²Ä 5844 ½g¦^À³
|
Ӯ׬ã¨s
finance.yahoo.com/quote/CNTB/ CNTB 2021/08/10 ¦¬½L»ù28.5¬ü¤¸¡A¥«È¬ù15.6»õ¬ü¤¸¡C¡]¸Ñª¼¸ê®Æ¤½§G«e¡^³o¬OCBP201 2b ¤¤¤@««×AD. ¸Ñª¼«eªº³Ì°ª»ù¡C CNTB ªÑ¥»¬ù5.5¸U¤dªÑADR ASLNªÑ¥»¬ù7¸U¤dªÑADR
¤j³°ªº¤½¥qªÑ»ù«Ü·|ª£¡I
2021/07/28 ¥Dn¼Æ¾Ú¦¬¶°§¹¦¨¡A¤½¥q¤wª¾¸Ñª¼¸ÑªG¡C
clinicaltrials.gov/ct2/show/NCT04444752?term=Cbp201&draw=2&rank=4
2021/11/19 ¤½§G¸Ñª¼µ²ªG¤£¦p¹w´Á¡GªÑ»ù¤j¶^¦Ü5¡A12¬ü¤¸¡C¥«È2¡D7»õ¬ü¤¸¡C
www.globenewswire.com/news-release/2022/01/05/2361507/0/en/Connect-Biopharma-Reports-Detailed-Positive-Dataset-from-the-Global-Phase-2b-Trial-of-CBP-201-in-Adult-Patients-with-Moderate-to-Severe-Atopic-Dermatitis.html ¥Dn«ü¼Ð Q2W *300mg
EASI75 47.4% vs 14.3% ®t²§30% IGA0,1 28.1% vs 10.7%(¹ï·Ó²Õ¡^®t²§18.1%
2023/01/04 ¦¬½L»ù0¡P86 ¥«È4700¸U¬ü¤¸
¤@¤@¤@¤@¤@¤@ ASLAN004 ³Ì¤jªÑªF Tang Capital ªº¦ÑÁó¬OµØ¸Ç ¨é°ÓH.C. Wainwright µ¹¤©¥Ø¼Ð»ù 7¬ü¤¸¡A ¤ÀªR®v ªºYi Chen¡GµØ¸Ç
004 ¸Ñª¼«e¯à§_¦pCNTB ¤j©Ô¨ì¥«È15¡D6»õ¬ü¤¸¡C¶W¹L20¬ü¤¸¡þªÑ¡^¡H¡H
Tang capital ¤jªÑªF¥[ªo¡I
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/1/5 ¤W¤È 08:45:33
²Ä 5843 ½g¦^À³
|
¹L¦~«e0.36¬ü¤¸ ¹L¦~¶È2¤Ñ«á¥Ø«e½L«á0.72¬ü¤¸
xx·|°µµu缐ªÌªº°]¯«¡Ixx
¨é°Ó«¦ù¥Ø¼Ð»ù7¬ü¤¸¡AÁÙ¦³9¿nº¦¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³v®ö«È10146323 |
µoªí®É¶¡:2023/1/4 ¤U¤È 10:49:22
²Ä 5842 ½g¦^À³
|
Aslan Pharmaceuticals (ASLN)
In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Aslan Pharmaceuticals, with a price target of $7.00. The company¡¦s shares closed last Tuesday at $0.44, close to its 52-week low of $0.34.
According to TipRanks.com, Chen has 0 stars on 0-5 stars ranking scale with an average return of -12.8% and a 29.2% success rate. Chen covers the Healthcare sector, focusing on stocks such as Bausch + Lomb Corporation, EyePoint Pharmaceuticals, and Greenwich LifeSciences.
Aslan Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $5.50.
ªü´µ兰¨î药¤½¥q (ASLN)
¦b¤µ¤Ñ发¥¬ªº报§i¤¤¡AH.C. WainwrightªºYi Chen«¥Ó¤F对Aslan Pharmaceuticalsªº买¤J评级¡A¥Ø标ɲ为7.00¬ü¤¸¡C该¤½¥qªºªÑɲ¤W©P¤G¦¬¤_0.44¬ü¤¸¡A±µªñ¨ä52©Pªº³Ì§C点0.34¬ü¤¸¡C
®ÚÕuTipRanks.comªº数Õu¡AChen¦b0-5¬Pªº±Æ¦Wªí¤W¦³0颗¬P¡A¥§¡¦^报²v为-12.8%¡A¦¨¥\²v为29.2%¡CChen负责医疗«O°·¦æ业¡A«点关ª`³Õ¤h伦¤½¥q¡BEyePoint¨î药¤½¥q©M®æªL«Âªv¥Í©R¬ì学¤½¥qµ¥ªÑ²¼¡C
ªü´µ兰¨î药¤½¥qªº¤ÀªR师¤@P认为¬OÓì«×买¤J¡A¥Ø标ɲ为5.5¬ü¤¸¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³v®ö«È10146323 |
µoªí®É¶¡:2023/1/4 ¤U¤È 12:54:56
²Ä 5841 ½g¦^À³
|
¬Q¤Ñº¦¤F20% ¨C¦¸¶^¯}0.4´N¬O¶R¡I ¥[ªo§a¡I²r·à¡I |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2023/1/4 ¤W¤È 11:34:35
²Ä 5840 ½g¦^À³
|
¥t 1.Thermo Fisher p¹º©ó 2023 ¦~ 1 ¤ë¶}©l¦b¨ä°Ó·~³W¼Òªº¨}¦n¥Í²£³W½d (GMP) »{ÃҥͲ£³]¬I¤¤¥Í²£·s°t¤è¡C 2. ¡K¡K¡A¦b TREK-AD ¬ã¨sŪ¥X«á¤£¤[´N¥i¥H¶i¤J²Ä 3 ¶¥¬q¡A¡K¡K
(ÅÞ¿è«ä¦Ò)¡G Thermo Fisher³o»ò¦(2023 ¦~1¤ë)´N¶}©l§ë¤J¥Í²£eblasakimab »s¾¯¡A§¹¥þ¨S¦³nµ¥©ú¦~TREK-DXªº¸Ñª¼¼Æ¾Ú ¥X¨Ó¦A¥Ñ¤½¥q¤½¥¬¤T´ÁÁ{§É¸ÕÅç®É¶¡ÂI¡C«á±ÁÙ±µµÛÁ¿¡A¦bTREK-AD ¬ã¨s¼Æ¾Ú¥X¨Ó«á¤£¤[´N¥i¥H¶i¤J²Ä3¶¥¬q¡C ³o¦X²z¡A¦]TREK-DXªº¸Ñª¼¼Æ¾Ú¡A¥u¬O¦h¼W¥[¨È·à±d³Q¨ÖÁʪº½Í§PÄw½X¡C ¹w´Á¤µ(112)¦~Q4±N°õ¦æ¤T´ÁÁ{§É¸ÕÅç¡An¨Ö¨È·à±dªº¤½¥q¡A¤â¸}n§Ö¡A·U±ß¨ÖÁÊ¡A¨ÖÁÊ»ù·U°ª¡C ¦ý ¨È·à±d³]pªº¤T´ÁÁ{§É¸ÕÅçpµe¡A¨äµ²ªG¡A§ñÃö¤§«áÃÄÃҥӽСA¾¯¶q¡B¦¨¥»µ¥¬Òn¦Ò¶q¡C ¨È·à±dªº¤T´ÁÁ{§É¸ÕÅçpµe¬O¤§«á¨ÖÁÊÃÄ°Ónªº¶Ü¡H À³¸Ó¬OÃÄ°Ó¨ÖÁʨȷà±d«á¡A¥ÑÃÄ°Ó´£¥X¥¦¦Û¤vªº¤T´ÁÁ{§É¸ÕÅçpµe¤~¦X²z¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/1/4 ¤W¤È 11:01:53
²Ä 5839 ½g¦^À³
|
Lebrikizumab ¤¤¤@««×AD ¤G½u(¥Î¹LdupilumabªÌ)¡B¤T´ÁÁ{§É
clinicaltrials.gov/ct2/show/NCT05369403?term=Lebrikizumab&draw=2&rank=3
¤W¤ë,2022/12/19¤é¤w¥¿¦¡¶}©l¬ã¨s
N=120¤H¡BOpen label(µL¹ï·Ó²Õ)
预p¤µ¦~10¤ë©³§¹¦¨¥Dn¸ê®Æ¦¬¶°¡D |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/1/4 ¤W¤È 10:02:31
²Ä 5838 ½g¦^À³
|
¸Ø±i¤j¡B
ASLAN004 2bÁ{§É¡B65Ó¦¬®×¤¤¤ß¡B ¨ä¤¤约¦³1/3¬O¦W¬°ASLNªº¦U¦a¦¬®×¤¤¤ß¡B¨C¦¸¥´°w«e¬Ò·|©â¦å¡D Y¦³¦å²G¤¤¤À§é¦b¤â¡B¥iª¾¨C¶g©Î¨C¤G¶gªº¦å²G¤¤ªºASLAN004ªºÃĦs¶q?
¦h©â´Xccªº¦å´N¦³§PÂ_¦UºØ¼Æ¾Ú¥i¯à??
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2023/1/4 ¤W¤È 09:46:15
²Ä 5837 ½g¦^À³
|
(ÅÞ¿è«ä¦Ò) ¨È·à±d§äThermo Fisher¡A¤£·|¬O¬Q¤Ñ§ä¨ìThermo Fisher´N¬Q¤Ñµo¥¬·s»D½ZÅý§Ú̪¾¹D¡C ¤@©w¬O¡§«e´XӤ롨´N¶}©l±µ¬¢Thermo Fisher¡A¦Ó¡§«e´XӤ롨¬O¦h¤[«e¡H ¨È·à±d¤â´¤¦hµ§ª¼¼Æ¾Ú¡Aª¼¼Æ¾Úªº¶q¤@©wn¹F´Á¤¤³ø§i³W¼Ò¡A 111/05/06¤½¥q¤½§i¦¨¥ß36Ó©Û¶Ò(¦¬®×)¤¤¤ß¡A§Y¹F´Á¤¤³ø§i©Ò»Ýªº¶q¡A¥B111/12/06¥H«á¥i¥H¸Ñª¼¡C ¨È·à±dªº±M®aÀ³¸Ó¬O111¦~11¤ë¥ª¥kµo²{¦¬®×¸ÕÅç¹ï¶H¤G´Á¸Ñª¼¨S°ÝÃD(¼Æ¾Ú¨S°ÝÃD)¡A ¥B¤w¨M©w¥Î°ª¿@«×ªº eblasakimab »s¾¯¨Ó©¹¤T´Á¸ÕÅç«e¶i¡A¤~·|¶i¤@¨B§äCDMO¤½¥q(Thermo Fisher)¦X§@¡A ¸g¹L111¦~12¤ë¦h¦¸»PThermo Fisher°ª¼h·¾³q¨S°ÝÃD¡A¤~·|¬Q¤Ñµo¥¬·s»D½ZÅý§Ú̪¾¹D¡C (µ²½×¡G112¦~Q2ªº¤G´Á¸Ñª¼¼Æ¾Ú¥¿¦V¬O¨S°ÝÃDªº)
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/1/4 ¤W¤È 07:36:08
²Ä 5836 ½g¦^À³
|
2023/01/03 02:54:09 ¸gÀÙ¤é³ø °OªÌÁ¬f§»¡þ¥x¥_³ø¾É
«O·ç¡]6472¡^ÃÄ·~¸³¨Æªø²±«Oº³ªí¥Ü¡Aªï±µ2023¦~·sªº¤@¦~¡A¥þ²y³q³f¿±µÈ¤´±N«ùÄò¡A³o¹ï»sÃIJ£·~«o¬OÀò§Q¤j¦¨ªøªº¦~«×¡A¬Ì±¡½w©M¤]¬° CDMO¡]©e°U¶}µo»P»s³yªA°È¡^¡K
Àç·~额¤O«÷300»õ¥x¹ô¡D(10»õ¬ü¤¸)
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/1/4 ¤W¤È 06:15:02
²Ä 5835 ½g¦^À³
|
TMO - Thermo Fisher Scientific Inc(¬ü°ê¤½¥q) ªÑ»ù553¬ü¤¸/ªÑ ¥«È2170»õ¬ü¤¸ ¦~À禬440»õ¬ü¤¸ û¤u13¸U¤H
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/1/4 ¤W¤È 05:42:21
²Ä 5834 ½g¦^À³
|
«ôµn·s¬Fµ¦ ¯{¹O20»õ¬ü¤¸·m»sÃÄ¥N¤uµo²yÅv ¬ü¥Í§Þ·~¡u§Ù¤¤°ê¡v ¥x¼tªïÂà³æ§Q¦h¡H 2022/09/21 www.businesstoday.com.tw/article/category/183015/post/202209210024/
¬ü°ê¹ï¤¤°êµo®iªº¾á¼~¡A¤w±q¥b¾ÉÅ驵¦ù¨ì¥Í§Þ»â°ì¡A¨ä¤¤¨¬°¤¤°ê³Ì¤j¥Í§Þ¤½¥qªºÃÄ©ú±d¼w(¥@¬É²Ä¤G¤jªºCDMO/À禬51»õ¬ü¤¸)¡A¦¨¬°¬ü°ê¬F©²²´¤¤ªº·¥¤j«Â¯Ù¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/1/3 ¤U¤È 10:51:52
²Ä 5833 ½g¦^À³
|
ibmi.taiwan-healthcare.org/zh/bio_highlights_detail.php?REFDOCTYPID=0qdjdurnc3gwcf04&REFDOCID=0rjonvnph8eitmo4 ¥þ²y¤Q¤jCDMD»sÃĤ½¥q 2022/10/17
Thermo Fisher Scientific Inc¡]¯Ã¬ùÃÒ¨é¥æ©ö©Ò¥N½X¡GTMO¡^¥þ²y CDMO±Æ¦W²Ä¥|¡A¦ôªñ40»õ¬ü¤¸¦~À禬¡C ¤j¤À¤l¶}µo¬ù9¡ã10Ó¤ë¡C ¤Wzºô¶¦³¸Ô²Ó¤¶²Ð |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/1/3 ¤U¤È 09:33:20
²Ä 5832 ½g¦^À³
|
Dupilumab ¥«³õ»ù®æ ¤TºØ¾¯«¬
¤@¡B 100 mg/0.67 mL Dupixent subcutaneous solution from $3,573.73 for 1.34 milliliters
¤G¡B 200 mg/1.14 mL Dupixent subcutaneous solution from $3,353.84 for 2.28 milliliters
¤T¡B 300 mg/2 mL Dupixent subcutaneous solution from $3,573.73 for 4 milliliters
www.drugs.com/price-guide/dupixent
¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K ¥¼¨ÓASLAN004 ±N¥Î400mg/2ml ªº¥Ö¤Uª`®g¨Ó°õ¦æ¤T´ÁÁ{§É¡C¡]¤@°w400mg°ª¿@«×ASLAN004) |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/1/3 ¤U¤È 09:05:52
²Ä 5831 ½g¦^À³
|
¤µ¤éASLN·s»D½Z
·s»D½Z ASLAN PHARMACEUTICALS ©M Thermo Fisher Scientific «Å§G«Ø¥ß¦X§@¹Ù¦ñÃö«Y¡A¬°¥¼¨Ó¬ã¨s¥Í²£ EBLASAKIMAB ªº°ª¿@«×»s¾¯ Thermo Fisher Scientific ´£¨Ñ¥Íª«»s³y±M·~ª¾ÃÑ©M©ñ¤j¯à¤O¡A¥HºÞ²z¥¼¨Ó 3 ´Á¬ã¨sªº eblasakimab Á{§É¨ÑÀ³ ±N»s³y°ª¿@«×ªº eblasakimab »s¾¯¡]200 ²@§J/²@¤É¡^¡A¥¦¥i¥H³q¹L³æ¦¸¥Ö¤Uª`®g´£¨Ñ°ª¹F 400 ²@§Jªº eblasakimab ¾¯¶q
¥[§QºÖ¥§¨È¦{¸t°¨¯S¶ø¥«©M·s¥[©Y¡A2023 ¦~ 1 ¤ë 3 ¤é¡X¡XASLAN Pharmaceuticals¡]¯Ç´µ¹F§J¥N½X¡GASLN¡^¡A¤@®a±Mª`©óÁ{§É¶¥¬q¡B¥H§K¬Ì¾Ç¬°«ÂIªº¥Íª«»sÃĤ½¥q¡AP¤O©ó¶}µo³Ð·sÀøªk¥H§ïÅܱwªÌªº¥Í¬¡¡AThermo Fisher Scientific Inc¡]¯Ã¬ùÃÒ¨é¥æ©ö©Ò¥N½X¡GTMO¡^ ¡^¡AªA°È¬ì¾Ç»â°ìªº¥þ²y»â¾ÉªÌ¡A¤µ¤Ñ«Å§G«Ø¥ß¦X§@¹Ù¦ñÃö«Y¡A¬° 3 ´ÁÁ{§É¸ÕÅç¥Í²£°ª¿@«×ªº eblasakimab »s¾¯¡C Eblasakimab ¬O¤@ºØ¼ç¦bªº¤@¬y³æ§J¶©§ÜÅé¡A¹v¦V IL-13 ¨üÅé¡A¦³¥i¯à¬°¤¤«×¦Ü««×¯SÀ³©Ê¥Öª¢¡] AD ¡^ªºªvÀø´£¨Ñ®t²§¤ÆªºÀø®Ä©M¦w¥þ©Ê¡C ¨È·à±d¤w¶}µo¥X¤@ºØ°ª¿@«×ªº eblasakimab »s¾¯¡A¤¹³\³æ¦¸¥Ö¤Uª`®gµ¹ÃÄ°ª¹F 400mg ªº eblasakimab¡A¾A¥Î©ó¤£¦Pªº³]³Æ¡C Thermo Fisher p¹º©ó 2023 ¦~ 1 ¤ë¶}©l¦b¨ä°Ó·~³W¼Òªº¨}¦n¥Í²£³W½d (GMP) »{ÃҥͲ£³]¬I¤¤¥Í²£·s°t¤è¡C ¡§»P¥Íª«»s¾¯»s³y»â°ìªº¥þ²y»â¾ÉªÌ Thermo Fisher «Ø¥ß¦X§@¹Ù¦ñÃö«Y¬O¤@Ó«nªº¾Ô²¤¨½µ{¸O¡A¦]¬°§Ú̱NÄ~Äò±À¶i eblasakimab ªº¶}µo¡A¥H¹ê²{¥þ²y 3 ´ÁÁ{§É¸ÕÅç¡C Thermo Fisher ¦b¥Íª«»s¾¯¶}µo¤è±¶i¦æ¤F¤j¶q§ë¸ê¡A¨Ã¦b 240 ¦hӥͪ«»s¾¯¶}µo¶µ¥Ø¤¤´£¨Ñ¤F 20 ¦~ªº¤uÃÀ¶}µo¸gÅç¡A¨Ã´£¨Ñ¥þ²y°ò¦³]¬I¨ÓÂX¤j¥Íª«»s¾¯»s³y¨Ã´£¨Ñ¥Í²£³sÄò©Ê¡A¡¨¨È·à±dº®u¹BÀç©x Kiran Asarpota »¡ ÃÄ«~¡C ¡§§Ú̬۫H§Ṳ́w¸g½T©w¤F³Ì¨Î¦X§@¹Ù¦ñ¡A¥i¥H¨Ï¥Î§Ú̪º·s°t¤è´£¨Ñ°ª½è¶qªºì®ÆÃÄ¡A³o¬O§Ṳ́@ª½¦bp¹ºªº¤@¶µÃöÁ䬡°Ê¡A¦b TREK-AD ¬ã¨sŪ¥X«á¤£¤[´N¥i¥H¶i¤J²Ä 3 ¶¥¬q¡A¤£·|¼vÅT §Ṳ́§«e³ø§iªº²{ª÷¶]¹D¡C¡¨
¡§»P ASLAN ªº³oºØ¦X§@¹Ù¦ñÃö«Y¬O§Ú̦p¦ó§Q¥Î¥@¬É¤@¬yªº¶}µo©M»s³y±M·~ª¾ÃѤj³W¼Ò´£¨Ñ³Ð·s°t¤èªº¤@Ó¨Ò¤l¡A¡¨Thermo Fisher »sÃĪA°È°Ó·~¹BÀçÁ`µô Leon Wyszkowski »¡¡C ¡§§Ú̪º§Þ³N¡A¥]¬A 5,000 ¤É¤@¦¸©Ê¥Íª«¤ÏÀ³¾¹ (SUB)¡A±N¥Î©ó»s³y·sªº°ª¿@«× eblasakimab »s¾¯¡A¨Ã±N¹ê²{§ó¤j³W¼Òªº¤@¦¸©Ê¯à¤O¡A¥Î©ó«á´Á¸ÕÅç©M³oºØ¼ç¤Oªº°Ó·~¤Æ ªvÀø AD ±wªÌ¡C¡¨ ASLAN ¥¿¦b¶i¦æ TREK-AD ¸ÕÅç¡A³o¬O¤@¶µ¥þ²yÀH¾÷¡BÂùª¼¡B¦w¼¢¾¯¹ï·Ó¡B¾¯¶q½d³ò¡B2b ´ÁÁ{§É¸ÕÅç¡A¥Hµû¦ô eblasakimab ¦b¦¨¤H¤¤«×¦Ü««× AD ±wªÌ¤¤ªºÀø®Ä©M¦w¥þ©Ê¡C ¸Ó¸ÕÅ窺³»½u¼Æ¾Ú¹wp±N©ó2023¦~²Ä¤G©u«×¤½§G¡C¸Ó¤½¥qÁÙ¦b¶i¦æ TREK-DX ¬ã¨s¡A¥Hµû¦ô eblasakimab ¦b¥ý«e±µ¨ü¹L dupilumab ªvÀøªº¤¤««× AD ¦¨¦~±wªÌ¤¤ªºÀø®Ä¡C TREK-DX ¬ã¨sªº³»½u¼Æ¾Ú¹wp±N©ó 2024 ¦~²Ä¤@©u«×¤½§G¡C
PRESS RELEASE ASLAN PHARMACEUTICALS AND THERMO FISHER SCIENTIFIC ANNOUNCE PARTNERSHIP TO MANUFACTURE HIGH CONCENTRATION FORMULATION OF EBLASAKIMAB FOR FUTURE STUDIES Thermo Fisher Scientific to provide biologic manufacturing expertise and scale-up capacity to manage the clinical supply of eblasakimab for future Phase 3 studies A high concentration formulation of eblasakimab (200mg/ml) will be manufactured which could enable doses of up to 400mg eblasakimab to be delivered via a single subcutaneous injection
San Mateo, California, and Singapore, January 3, 2023 ¡V ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, and Thermo Fisher Scientific Inc (NYSE: TMO), the world leader in serving science, today announced a partnership to manufacture a high concentration formulation of eblasakimab for Phase 3 clinical trials. Eblasakimab is a potential first-in-class monoclonal antibody targeting the IL-13 receptor that has the potential to deliver a differentiated efficacy and safety profile for the treatment of moderate-to-severe atopic dermatitis (AD). ASLAN has developed a high concentration formulation of eblasakimab, allowing up to 400mg eblasakimab to be administered in a single subcutaneous injection and suitable for use with different devices. Thermo Fisher plans to commence manufacturing the new formulation in its commercial-scale Good Manufacturing Practices (GMP) certified manufacturing facilities in January 2023. ¡§Establishing this partnership with Thermo Fisher, a global leader in biologics manufacturing, is an important strategic milestone as we continue to advance the development of eblasakimab towards global Phase 3 clinical trials. Thermo Fisher has made deep investments in biologics development and offers 20 years of process development experience in over 240 biologics development programs, as well as a global infrastructure to scale up biologics manufacturing and deliver production continuity,¡¨ said Kiran Asarpota, Chief Operating Officer, ASLAN Pharmaceuticals. ¡§We are confident we have identified the best partner to deliver high-quality drug substance with our new formulation, a critical activity we have been planning for to be Phase 3 ready soon after the readout from the TREK-AD study, with no impact on our previously reported cash runway.¡¨
¡§This partnership with ASLAN is an example of how our world-class development and manufacturing expertise can be used to deliver innovative formulations at scale,¡¨ said Leon Wyszkowski, Thermo Fisher¡¦s President of Pharma Services Commercial Operations. ¡§Our technology, including the 5,000-L Single-Use Bioreactor (SUB), will be used to manufacture the new high concentration formulation of eblasakimab and will enable larger-scale, single-use capabilities for late-stage trials and commercialization of this potential treatment for AD patients.¡¨ ASLAN is conducting the TREK-AD trial, a global randomized, double-blind, placebo-controlled, dose-ranging, Phase 2b clinical trial, to evaluate the efficacy and safety of eblasakimab in adult patients with moderate-to-severe AD. Topline data from this trial is expected in the second quarter of 2023. The company is also conducting the TREK-DX study to evaluate eblasakimab in adult patients with moderate-to-severe AD who have previously been treated with dupilumab. Topline data from the TREK-DX study is expected in the first quarter of 2024. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2023/1/3 ¤U¤È 08:27:16
²Ä 5830 ½g¦^À³
|
·PÁ¸رi¤j¾ã²zªº®Éµ{ªí §Ú·Q«ùªÑ³o»ò¤[ ¤£½×µ²ªG¬O¦¨¬O±Ñ ³o¤]¬O¨È·à±dªº³Ì«á¤@ù¸ô¤F ªÑ»ù¥Ø«e¦b³Ì§CÂI±r«Þ¡A§Æ±æ·à¤ÍÌ2023¯à°fÂà³Ó |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2023/1/3 ¤U¤È 12:41:30
²Ä 5829 ½g¦^À³
|
Æ¡ 1¤ë10¤éª÷¤s¶}·| Æ¢ 1¤ë31¤éªÑªF·|(°Q½×ªÑ¥»¼W¸ê¤@¿) Æ£ 2¤ë15¤é𤽥q¹ï¨È·à±d111¦~²Ä¥|©u«ùªÑ©ú²Ó´¦ÅS Ƥ¦ô2¤ë¤¤¦¯~3¤ë¤W¦¯¡G¤½¥q·|¥ý¸Ñª¼ Æ¥ 3¤ë¤¤¦¯´¦ÅS¥h¦~¥þ²y¤Q¤jºZ¾PÃĪ«(Dupilumab±N¥X¦C) Ʀ 3¤ë¨p¶Ò Ƨ 4¤ë¤½¥¬¸Ñª¼¼Æ¾Ú ƨ 4¤ë¼Ú¬w°Ï±ÂÅv Æ© 5¤ë15¤é𤽥q¹ï¨È·à±d²Ä¤@©u«ùªÑ©ú²Ó´¦ÅS ƪµ¥³Q¦¬ÁÊ(¨S¿ú»\¦Û¤vªºÃļt¡A¥u¯à³Q¦¬ÁÊ)
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/1/3 ¤W¤È 09:52:41
²Ä 5828 ½g¦^À³
|
×¥¿¤@ ©Ò¿×ªºASLAN004 2b ¸Ñª¼¦p预´Á ´N¬O¦p1b mITT
IGA0,1=45% vs 15%(¹ï·Ó组) ®t²§30% (¹êÅç组16¶g¦³¤j¾÷·|¹F50%~60%, ®t²§33%¤~²Å¦X预´Á¡B¹êÅç组¶·¹F33%+15%=48%)
EASI75=69% vs 15%(¹ï·Ó组) ®t²§54% (2bªº¹ï·Ó组16¶gEASI75¦ôªñ 24%, ¹êÅç²Õ¬ù65%,®t²§41%¥H¤W¡B¤~²Å¦X¥«³õ预´Á)
ASLAN004 2b IGA0,1¤ÎEASI75 ©M¹ï·Ó组ªº®t²§Àu©óLebrikizumab10%¥H¤W¡B ¤~²Å¦X¥«³õ预´Á, ³Ì°ª¨é°Ó¥Ø¼Ð»ù7¬ü¤¸/ªÑ ¡K¡K¡K¡K¡K Lebrikizumab 2b Q2W EASI75=61% vs24%(¹ï·Ó组)¡B®t²§37% IGA0,1=45% vs 15%(),®t²§30%
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/1/3 ¤W¤È 09:45:15
²Ä 5827 ½g¦^À³
|
©Ò¿×ªºASLAN004 2b ¸Ñª¼¦p预´Á ´N¬O¦p1b mITT
IGA0,1=45% vs 15%(¹ï·Ó组) ®t²§30% (¹êÅç组16¶g¦³¤j¾÷·|¹F50%~60%)
EASI75=69% vs 15%(¹ï·Ó组) ®t²§54% (2bªº¹ï·Ó组16¶gEASI75ªñ 24%, ¹êÅç²Õ ¬ù65%,®t²§45%¥H¤W¡B¤~²Å¦X¥«³õ预´Á)
ASLAN004 2b IGA0,1¤ÎEASI75 ©M¹ï·Ó组ªº®t²§Àu©óLebrikizumab10%
¤~²Å¦X¥«³õ预´Á,³Ì°ª¨é°Ó¥Ø¼Ð»ù7¬ü¤¸/ªÑ ¡K¡K¡K¡K¡K Lebrikizumab 2b Q2W EASI75=61% vs24%(¹ï·Ó组)¡B®t²§37% IGA0,1=45% vs 15%(),®t²§30%
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/1/2 ¤U¤È 05:48:40
²Ä 5826 ½g¦^À³
|
Lebrikizumab 2b
1.Percent Change From Baseline in Eczema Area and Severity Index (EASI) Q2W 72% vs 41%(¹ï·Ó²Õ) P=0.0005
Q4W 69% vs41% P=0.0022
2.IGA0,1
Q2W 45%vs15%(¹ï·Ó组) P=0.0023
Q4W 34%vs 15% P=0.0392 (Lebrikizumab ¤T´ÁÁ{§É¨Ã¥¼°µ1-16¶gªºQ4W)
clinicaltrials.gov/ct2/show/results/NCT03443024
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2023/1/2 ¤W¤È 10:32:17
²Ä 5825 ½g¦^À³
|
·s¦~·s°ø±æ 1.§Æ±æ¶V§Ö¶V¦n¦³¥¿¦V´Á¤¤¼Æ¾Ú¨Ñ°Ñ¦Ò¡A§Yªí¥Ü¤U°ø±æ¦¨¥\¾÷·|¤j¡C 2.¸Ñª¼®É¾ãÅéPȤp©ó0.05 3.¥|¶g¤@°w¸ÕÅç²Õ§CªÅ§C©ó0.05§Y¥i 4.¦Ü¤Ö¤@ªÑ4.5¶ô¼W¸ê |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GDHL10147526 |
µoªí®É¶¡:2023/1/1 ¤W¤È 09:05:44
²Ä 5824 ½g¦^À³
|
·s¦~·s§Æ±æ
¨È·à±d ¸Ñª¼¦¨¥\¡A¼W¸ê¶¶§Q¡A¤j®aµo¤j°]¡I
¯¬¤j®a·s¦~§Ö¼Ö¡I°]·½ºuºu¡I¨Åé°·±d¡I |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/1/1 ¤W¤È 08:56:12
²Ä 5823 ½g¦^À³
|
2023/01/31 ªÑªF·|¡B¸ê¥»额¼W¤@¿¡D ¦ô2¤ë¤¤¦¯~3¤ë¤W¦¯¡B¤½¥q·|¥ý¸Ñª¼.
±µµÛ¨p¶Ò 4¤ë¤½¥¬¸Ñª¼¼Æ¾Ú¡B ¥]¾P ¡K¤j¶Ò¸ê¡D
¤@¤Á¨Ì¸Ñª¼¼Æ¾Ú²Å¦X预´Á¬°¥²n±ø¥ó¡D ¥un400mg*Q2W(¤G¶g¤@°w)¦X¥G预´Á§Y¥i¡D
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2022/12/31 ¤W¤È 07:30:25
²Ä 5822 ½g¦^À³
|
§Ö¯}«e§C¡AÁÙ¦³±Ï¶Ü
·sªº¤@¦~³Ì«áªº¾÷·|
¯¬¦U¦ì·s¦~·s§Æ±æ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/12/23 ¤U¤È 07:18:11
²Ä 5821 ½g¦^À³
|
×¥¿¤@¡B ASLAN004 VS Lebrikizumab ®Ä²vPK//2b ¥DnÀø®Ä«ü¼Ð´Á±æÈ
Lebrikizumab 2Ó¤T´Á: ¨C¤G¶g¤@°w. www.almirall.com/documents/portlet_file_entry/4257831/300322_ORI+Lebri+pres+ENG+%2B+pres+vf.pdf/5ad7034f-0dd9-492f-eb83-1515071417de
ASLAN004 1b mITT :¨C¶g¤@°w aslanpharma.com/wp-content/uploads/2022/09/EADV-Efficacy-Outcomes-poster_FINAL-1.1.pdf
¤@.Àø®Ä®Ä²v²Ä¤K¶g¤§PK(¦©°£¹ï·Ó²Õ) 1.EASI75 ASLAN004 69%-15%=54%-----A VS LEB. 50%-15%=35%,-----B
Leb. ªºEASI75 ¦b²Ä8¶g´î±Ó®Ä²v¶È ASLAN004 ªº65% (B:35%/A:54%=65% )
***ASLAN004 ªýÂ_IL4 & IL13 °T¸¹¯à¤O±j¦b²Ä8¶gªºEASI75Àø®Ä69%ªí²{¤ñLebrikizumab,16¶g59%Àu(8¶g=50%). ***Lebrikizumab,IGA0,1 ,Àø®Ä ²Ä8¶g30%. 16¶g43%. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/12/23 ¤U¤È 04:52:42
²Ä 5820 ½g¦^À³
|
ASLAN004 VS Lebrikizumab ®Ä²vPK//2b ¥DnÀø®Ä«ü¼Ð´Á±æÈ
Lebrikizumab 2Ó¤T´Á: ¨C¤G¶g¤@°w. www.almirall.com/documents/portlet_file_entry/4257831/300322_ORI+Lebri+pres+ENG+%2B+pres+vf.pdf/5ad7034f-0dd9-492f-eb83-1515071417de
ASLAN004 1b mITT :¨C¶g¤@°w aslanpharma.com/wp-content/uploads/2022/09/EADV-Efficacy-Outcomes-poster_FINAL-1.1.pdf
¤@.Àø®Ä®Ä²v²Ä¤K¶g¤§PK(¦©°£¹ï·Ó²Õ) 1.EASI75 ASLAN004 69%-15%=54%-----A VS LEB. 50%-15%=30%,-----B
Leb. ªºEASI75 ¦b²Ä8¶g´î±Ó®Ä²v¶È ASLAN004 ªº55% (B:30%/A:54%=55% )
***ASLAN004 ªýÂ_IL4 & IL13 °T¸¹¯à¤O±j¦b²Ä8¶gªºEASI75Àø®Ä69%ªí²{¤ñLebrikizumab,16¶g59%Àu(8¶g=50%). ***Lebrikizumab,IGA0,1 ,Àø®Ä ²Ä8¶g30%. 16¶g43%.
ASLAN004 2bÁ{§É «e¤T°w, «e26¤Ñ~29¤Ñ«Oµý§¹¥þ§í¨îIL13Ra1ªºª¬ªp¤U, ¦ô¨Ï¾ãÅ骺¤ÏÀ³¥§¡°EASI¹Fªñ60%~65%¤U,EASI75¦ôªñ50%. (¬Û·í©óLebrikizumab ²Ä¤K¶gªºÀø®Ä.), ¦ôIGA0,1 ¥i°¦Ü30%.
---TRAC¤w»â¥ý¤U°¶W¹L70%.
ASLAN004 2b *Q2W*300mg /400mg ²Ä29¤Ñ(²Ä¥|¶g)~112¤Ñ(²Ä16¶g),¦ô±N¨Ï (1)¥§¡EASI¥Ñ²Ä¥|¶g60%~65%¤U°¨ì²Ä16¶gªº85%¥ª¥k,
(2)EASI75¥Ñ²Ä¥|¶g50%¤U°¦Ü²Ä16¶gªº69%~73%
(3)³Ì«nªºIGA0,1 ,¥Ñ²Ä¥|¶g30%¤U°¦Ü²Ä16¶g, 53%~60%. ***Lebrikizumab,IGA0,1 ,Àø®Ä ²Ä8¶g30%. 16¶g43%.
¦³¥t¥~ªº12¶g(6°w)ªº®É¶¡¥R¤À¤ÏÀ³,¥i¨ÏIGA0,1(ªñEASI88~85)Àø®Ä¹F¥Ø¼Ð53%~60%
------------------------------------------ ASLAN004 2b Q2W ¥Ø¼Ð¥DnÀø®Ä«ü¼Ð´Á±æÈ
EASI75 69%~73%//24%(¹ï·Ó²Õ) IGA0,1 53%~60%//15%(¹ï·Ó²Õ)
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/12/22 ¤U¤È 05:56:32
²Ä 5819 ½g¦^À³
|
Lebrikizumab + TCS ,2022/10/18 , ¶}©l 3 ´ÁÁ{§É, 0.5~17·³*N=300¤H
clinicaltrials.gov/ct2/show/NCT05158023
A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
Actual Study Start Date : October 18, 2022 Estimated Primary Completion Date : July 15, 2024 Estimated Study Completion Date : August 15, 2025
1.Experimental: Lebrikizumab (Cohort 1) Participants who are 6 years to <18 years of age, 12 years to <18 years of age who weigh <40 kilogram (kg) or 6 years to <12 years of age (may weigh ≥40 kg) will receive a loading dose and then subsequent doses by subcutaneous (SC) injections with a topical corticosteroid (TCS).
Dosing will be based on weight.
Drug: Lebrikizumab Administered SC Other Names: LY3650150 DRM06
Drug: Topical corticosteroid Topical corticosteroid
2.Experimental: Lebrikizumab (Cohort 2) Participants who are 6 months to <6 years of age, 2 years to <6 years of age or 6 months to <2 years of age will receive a loading dose of lebrikizumab and then subsequent doses by SC injections with a TCS.
Dosing will be based on weight.
Drug: Lebrikizumab Administered SC Other Names: LY3650150 DRM06
Drug: Topical corticosteroid Topical corticosteroid
3.Placebo Comparator: Placebo Participants will receive placebo matching lebrikizumab by SC injections with a TCS.
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/12/22 ¤W¤È 09:12:01
²Ä 5818 ½g¦^À³
|
2021/¤¸¤ë/29 ¤é ´£¥X1»õ5¥a¸U¬ü¤¸ªº¶Ò¸êp¹º,¦p¤W ir.aslanpharma.com/static-files/a3f199f7-f90f-43e0-8068-18a04a09edc5
2021/02/24 ¨p¶Ò3.52¬ü¤¸/ªÑ ir.aslanpharma.com/static-files/8e211cfa-512e-4f27-b382-dea0efcc2e14
2021/03/01 ¤½§G1b´Á¤¤¼Æ¾Ú ir.aslanpharma.com/static-files/73f9ba3a-6822-48e5-ba31-886e0617b68d
2021/03/02 ¥]¾P4¬ü¤¸/ªÑ ir.aslanpharma.com/static-files/3e007d02-a765-4a15-83c3-47aa257d8f49
¦ôp¤¸¤ë©³¥H«e,¤w¥ý¸Ñª¼1b´Á¤¤¼Æ¾Ú.
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/12/22 ¤W¤È 06:22:33
²Ä 5817 ½g¦^À³
|
¨Ì®Éµ{ ²Ä¤@µ§¨p¶Ò±N¦b2023¦~3¤ë15¤é¥H«e§¹¦¨¡B§_«h¥²¶·´î¸ê¡D »ù®æ¡G7*80%*92%=5.15¬ü¤¸/ªÑ
³o¬O2021/02©³ªº¼Ò¦¡ 5x80%x92%=3.68....¨p¶Ò 2021/03/3...4¬ü¤¸¥]销
¦Ó·í®É¤¸¤ë©³¶}©lº¦¡D
¦ô¤½¥q¦b¥|¤ëªì¤½§G2b¼Æ¾Ú¡B¨Ã¥]销¨é°Ó¶Ò¥H«á¤T´Á¸êª÷¡D
³Q¨ÖÁʮɾ÷¦b©ú¦~©³!
¦³¸êª÷°µ¤T´ÁÁ{§É¤~·|¦³¦nªº³Q¨ÖÁÊ»ùÈ¡D ¥H¤WÓ¤H¬Ýªk!
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/12/21 ¤U¤È 09:45:29
²Ä 5816 ½g¦^À³
|
¤jx¥¼°Ê¡B³¯ó¥ý¦æ!
¤½¥q»ùÈ´N¦b15~25¬ü¤¸/ªÑ¤§¶¡¾÷·|¤j¡D
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/12/21 ¤U¤È 09:35:39
²Ä 5815 ½g¦^À³
|
¦p³Q¨ÖÁÊ»ù40»õ¬ü¤¸ 20¸UªÑADRªÑ¥»
¨CªÑ³Ñ20¬ü¤¸¡D
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/12/21 ¤U¤È 09:28:10
²Ä 5814 ½g¦^À³
|
¦n®ø®§¡I ¤£·|´î¸ê¤F¡C ¤@¤@¤@¤@ ©M¥H«e¤@¼Ë¡A¼W¥[¤@¿¸ê¥»ÃB¡A ADR±q10¸U¤dªÑ¼W¬°20¸U¤dªÑ¡C ¥Ø«e¤wµo¦æªñ7¸UªÑ¤dªÑADR ¡]¤½¥q¤º³¡¤Hû奬Ày¤@¸UªÑ¡^ ¥i¹ï¥~¶Ò12¸UªÑ¤d¤dªÑADR
¦p¨é°Ó¥Ø¼Ð»ù7¬ü¤¸¡C ¥]¾P»ù5.6¬ü¤¸¡C
5.6¬ü¤¸x12¸U¤dªÑ¡×ªñ6»õ7¤d¸U¬ü¤¸¡]¤@¦¸¶Ò§¹¡^
¶Ò¸ê5¡ã6»õ¬ü¤¸°µ¤T´Á¤Î¥ICSL3¤d¸U¬ü¤¸ªºqª÷¤Q ÁÙ·s¥[©Y°]¬F³¡ªºÉ´Ú¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2022/12/21 ¤U¤È 09:03:32
²Ä 5813 ½g¦^À³
|
2023¦~1¤ë31¤é¥l¶}Á{®ÉªÑªF¤j·|ªº³qª¾¤½§i
2022 ¦~ 12 ¤ë 21 ¤é¡AASLAN Pharmaceuticals Limited¡]¡§¤½¥q¡¨¡^µo¥XÁ{®ÉªÑªF¤j·|³qª¾¡]¡§³qª¾¡¨¡^±N©ó·í¦a®É¶¡ 2023 ¦~ 1 ¤ë 31 ¤é¤W¤È 9 ÂI¦b 3 Temasek Avenue Á|¦æ , Level 18 Centennial Tower, Singapore 039190 ¬°¦Ò¼{¨Ã°u±¡³q¹L¥H¤UªÑªF¨Mij¡G
¨Mij 1¡G
(i) §@¬°¤@¶µ´¶³q¨Mij¡A¼W¥[¤½¥qªºªk©wªÑ¥»¡G
(A) ¨Ó¦Û¡G5,000,000 ¬ü¤¸¤À¬° 500,000,000 ªÑ´¶³qªÑ¡A¨CªÑ±È©Î±È¬° 0.01 ¬ü¤¸¡C
(B) TO¡G10,000,000 ¬ü¤¸¤À¬° 1,000,000,000 ªÑ´¶³qªÑ¡A¨CªÑ±È©Î±È¬° 0.01 ¬ü¤¸¡C
¨Mij 2¡G
(ii) §@¬°¤@¶µ¯S§O¨Mij¡A¤½¥q²{¦³ªº²Õ´³¹µ{¤jºõ©M²Ó«h¡]§Y¤½¥qªº²Ä¤Q¦¸×q©M«zªº²Õ´³¹µ{¤jºõ©M²Ó«h¡^¥þ³¡¥Ñ·sªº²Õ´³¹µ{¤jºõ©M²Ó«h¡] ¬O¤½¥qªº²Ä¤Q¤@¦¸×q©M«z²Õ´³¹µ{¤jºõ©M²Ó«h¡^¡C
Ãö©ó¨Mij 2 ªº¸ÑÄÀ¡G¹ï¤½¥q²Õ´¤jºõ©M²Ó«hªºÀÀijקï¶È©ó¥H¤U¤º®e¡G
(a) Åܧ󤽥q³¹µ{¤jºõ²Ä 7 ±ø¡A»¡©ú¤½¥q¸ê¥»¡A¥H¤Ï¬M¤Wzªk©wªÑ¥»ªº¼W¥[¡F ©M
(b) ¨C¦¸³q½g¨Ï¥Î§ó·s«áªºµu»y¡§¤½¥qªk¡¨¥N´À¡§¤½¥qªk¡¨¡C
¸Ó³qª¾ªº°Æ¥»§@¬°ªþ¥ó 99.1 ªþ¦b¦¹³B¡AÀÀijªº²Ä¤Q¤@¦¸×q©M«zªº¤½¥q²Õ´³¹µ{¤jºõ©M²Ó«hªº°Æ¥»§@¬°ªþ¥ó 99.2 ªþ¦b¦¹³B¡A¦¹Ãþªþ¥ó³q¹L¤Þ¥Î¨Ö¤J¥»¤å¡C¥»¤å¥ó¤¤¥]§tªº«H®§ ªí®æ 6-K ¯S¦¹³q¹L¤Þ¥Î¯Ç¤J¤½¥qªí®æ F-3 ªºµù¥UÁn©ú¡]¤å¥ó½s¸¹ 333-252575¡^¡Bªí®æ F-3 ªºµù¥UÁn©ú¡]¤å¥ó½s¸¹ 333-254768¡^¡Bªí®æ S- ªºµù¥UÁn©ú 8¡]¤å¥ó½s¸¹ 333-252118¡^©Mªí®æ S-8 ¤Wªºµù¥UÁn©ú¡]¤å¥ó½s¸¹ 333-263843¡^¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/12/19 ¤U¤È 12:48:18
²Ä 5812 ½g¦^À³
|
¸Ø±i¤j¡C
¥Ø«e°ê»Úªº¦ôºâ»Ý¥ý¦©°£¹ï·Ó²ÕªºÀø®Ä¦A¤ñ¸û¤èªk¸û¦h¡G
EASI75 69% vs 24%(¹ï·Ó²Õ¡^¡A¡]¦©°£¹ï·Ó²Õ69%-24%=45%¡^ IGA0,1 53% vs 15%(¹ï·Ó²Õ¡^¡A¡]¦©°£¹ï·Ó²Õ53%-15%=38%¡^
Dupilumab 2Ó¤T´Á.¦©°£¹ï·Ó²Õ«á EASI75=36% IGA0,1=28%
ASLAN004 vs Dupilumab
EASI75 45%¡þ36%=125% IGA0,1 38%/28%=135%
µ²½×¡G¤T´ÁÁ{§Éªº¥Dn«ü¼Ð¡AASLAN004¦³Ä¹¹LDupilumab ¼Ð·ÇÀøªk25%¡ã35%ªºÁͶաC |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2022/12/19 ¤U¤È 12:04:02
²Ä 5811 ½g¦^À³
|
¥»¤å¥ýº¡¨¬¨â±ø¥ó¡G 1.©ú¦~¤G´Á¸Ñª¼¼Æ¾Ú¥¿¦V¡C 2.·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/8/11 ¤U¤È 04:00:38 ¥Ø«e§ä¤£¨ìÃÄÃÒ¤£¹Lªº²z¥Ñ¡I (©ú¦~¤G´Á¸Ñª¼¼Æ¾Ú)EASI75ªºÀø®ÄASLAN004Àu©óDupilumab40%¡]69%/48.5¢H¡^¡A¨º004ªºÃÄÃÒ»ùÈ´N«D±`¡B«D±`°ª¡C ----------------------------------------------------------------------ÅÞ¿è°Q½×¦p¤U--------------------------------------------------------------------- ¤£§@TREK-DX¤§«e¡A¨ä¹êTREK-ADªº¸Ñª¼¼Æ¾Ú´N°÷Ãļt¤U¨ÖÁʨMµ¦¤F¡A ·f°t©ú¦~²Ä¤@©uÁɿյ᤽¥¬Dupilumab ¤µ(111)¦~¾P°âÃB(111¦~¥þ²y«e¤Q¤jºZ¾PÃÄ)¡A Ãļt®Ú¥»¤£»ÝnTREK-DXªº¸Ñª¼¼Æ¾Ú¡A (TREK-DXªº¸Ñª¼¼Æ¾Ú¡A¬OÅý¨È·à±d´£°ª³Q¨ÖÁʪ÷ÃB¥Îªº) YTREK-DX¼Æ¾Ú¥¼¤½¥¬«e´N³Q¨Ö¡A¨È·à±d¤]·|§âTREK-DX¼Æ¾Ú¸Ó¦³ªº»ùÈ¥[¦b¨ÖÁʪ÷¸Ì±(Ãļt¤]·|»{¦P)¡C (¤£¬Û«H©Ò¦³Ãļtªº¯à¤O³£nµ¥TREK-DXªº¸Ñª¼¼Æ¾Ú¥X¨Ó) YEASI75ªºÀø®ÄASLAN004Àu©óDupilumab20%¥H¤W¡AÃļt¨ä¹ê´N¥i¥H¨ÖÁʨȷà±d¤F¡A (®Ú¥»¤£¥Î¦Ò¼{TREK-DX·|¸Ñª¼¦¨¥\©Î¥¢±Ñ)¡A (TREK-DX¸Ñª¼¦¨¥\¡GÀ³¸Óªº¡C¹ï¶H³£¬O¶Ç²Î«¬¯f±w) (TREK-DX¸Ñª¼¥¢±Ñ¡GÃļt¥H«á¥é³æ¥[µùĵ»y¡G¸T¥Î¹ï¶H¬°´¿¨Ï¥ÎDupilumab¯f±w) Ãļt¥unª¾¹DASLAN004Àø®Ä¡B¼Ú¬w°Ï±ÂÅvª÷ÃB©MDupilumab¤µ(111)¦~¾P°âÃB´N°÷¤F¡C ©Ò¥H¨È·à±d³Ì¦³¥i¯à³Q¨ÖÁʮɶ¡¡GTREK-AD¼Æ¾Ú¤½¥¬«á¦ÜTREK-DX¼Æ¾Ú¤½¥¬«e¡C (Åwªï¦U¦ì¤j¤j¤@¦P°Q½×)
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/12/19 ¤W¤È 11:01:52
²Ä 5810 ½g¦^À³
|
¥xÁÞ¤j
Dupilumab 2b ¦³´ú300mg ¥|¶g¤@°w¡A¨äIGA0,1¶È2¶g¤@针x300mgªº70%.
¡]Dupilumab ¤@°wªºPK¥i¶W¹L29¤Ñ¡C¡^
ASLAN004 1A x¤@°w¡A600mg x6¤H¡]¨ä¤¤5¤H¶È15¤Ñªº§¹¥þ§í¨î¡A¡^ ¨ä¤¤2¤H²Ä28¤Ñ§¹¥þ§í¨î ¨ä¤¤1¤H¥i¹F25¤Ñ§¹¥þ§í¨î ¨ä¤¤2¤H¡A¥i¹F18¤Ñ§¹¥þ§í¨î ¨ä¤¤1¤H¡A¥i¨ì13¤Ñ§¹¥þ§í¨î Q4wx600mg IGA¦³Q2W ªº50%´Nºâ¼F®`¤F¡C ¥H¤WÓ¤H±À´ú¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2022/12/19 ¤W¤È 10:31:51
²Ä 5809 ½g¦^À³
|
¤Ñ©R¤j
¤½¥q¦³´ú¸Õ300mg 400mg¨â¶g£¸°w»P400mg 600mg¥|¶g£¸°w , ¥|¶g£¸°w¥Ø«eÁÙ¨S¦³ÃĪ«¤W¥« , ¬D¾Ô¬Ý¬Ý¦A»¡ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/12/19 ¤W¤È 10:11:34
²Ä 5808 ½g¦^À³
|
±À½× ¤@¡BASLAN004 2bxQ2W 0/1/2°wx300mg ¦ô¥i°EASI,²Ä¥|¶g(²Ä29¤Ñ)
**¨Ì1b 400mgxQ1Wx6¤H结ªG±À¦ô¡B 65%x2¤H 63%x2¤H 61%x1¤H 59%x1¤H ¥§¡EASI ¤U°62%
¤G¡B2b 400mgxQ2W¦ô ¡B²Ä29¤Ñ 65%*4¤H 63%x1¤H 61%x1¤H ¥§¡EASI ¤U°64%
¥H¤W300mg/400mg ¦b²Ä¥|¶g(²Ä29¤Ñ)¥´²Ä¥|°w¡B¦b²Ä¤»¶g(²Ä43¤Ñ)¥i¸É¦^«e±3%/1%ªº¸¨®t¡D
EASI ¥§¡°¦Ü71%.
ir.aslanpharma.com/static-files/5af23249-0b59-4bb1-95eb-199556171feb
Q2WªºÀø®Ä¥i´Á¡B¦³°ª¾÷·|¶W¶V1bªº8¶gªvÀøªºÀø®Ä¡D |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/12/19 ¤W¤È 08:19:59
²Ä 5807 ½g¦^À³
|
¸É¥R¤G¡B patents.google.com/patent/WO2020197502A1
¹Ï10 scx300mg ÃĮľÇÁͶչÏx6¤H
2¤H§¹¥þ§í¨î¨ì²Ä15¤Ñ¡B¦ô³Ì°ª¨ì18¤Ñ 2¤H§¹¥þ§í¨î¨ì²Ä14¤Ñ, ²Ä14¤ÑªºSTART6¤U´åÁͶդÀ¤l¤Ï¼u15%,ÃĮľÇPK³Ñ85%.
1¤H§¹¥þ§í¨î¨ì²Ä13¤Ñ, ²Öp2¤ÑSTART6¼Æ¶q¤Ï¼u45%,ÃĮľÇPK³Ñ55%. 1¤H§¹¥þ§í¨î¨ì²Ä12¤Ñ¡B²Öp3¤ÑSTART6¼Æ¶q¤@¤Ï¼u90%,ÃĮľÇPK³Ñ10%.
¥H¤WÆ[¹î¡BÃĮľÇPK¨C¤Ñ15%¤Ï¼u¡D²Öp3¤Ñªñ90%ªºÃĮķl¥¢¡B¶È¯à§í¨î10%.
ASLAN004 SC¥Ö¤Uª`®gªº¥Í¦¨²v¤j¬ù¶È30%(¥´¤J¨Å骺ÃĶq³Ì«á¶i¤J¦åºÞªº¤ñ²v¶È30%.Dupilumab¬ù50%)
ASLSN004§¹¥þ§í¨î¦åºÞ¤¤ÃĶq=1mg/L=1000ng/ml
¹Ï12b«Ü«n¡BSC ¦U¾¯¶qªºPK¥Í©R¹Ï¡D |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/12/18 ¤W¤È 05:11:29
²Ä 5806 ½g¦^À³
|
IV10mg/kg: ÀR¯ßª`®g¡BÅ髨C¤½¤ç¥´10mg. 60¤½¤ç¥´¤J¦åºÞ¤¤ÃĶq10x60=600mg
70¤½¤ç¥´¤JÃĶq700mg
SC600mg:¥Ö¤Uª`®g600mg
°²³]¶i¤J¦åºÞÃĶq50%(¥Í¦¨²v),¨ä¥L³Q¨Åé§l¦¬¡D
600*50%=300mg¶i¤J¦åºÞ
¥B¤£ºÞ§AÅ髦h¤Ö¡B¥´¤J¨ÅéÃĶq©T©w¡D
¤@Ó±wªÌSC600mg,¶i¤J¦åºÞÃĶq¬ù300mg (sc¥Í¦¨²v°²³]50%)¡B¬Û·í¥´ IV5mg/kg¦Ó¤w¡D |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/12/18 ¤W¤È 03:33:18
²Ä 5805 ½g¦^À³
|
¥xÁÞ¤j¡B IV 10mg/kg ¥i§¹¥þ§í¨î29¤Ñªº³ø§i¬O¥¿½Tªº¡D
¦ýSC 600mg ªº§¹¥þ§í¨î¦b³ø§i¤¤6¤H¡B¶È5¤H¨ì²Ä15¤Ñ¡B¥t¤@¤H¨ì²Ä8¤Ñ¡B
¹Ï12b¦³dupilumab vs aslan004 Sc pk ÁÍ¶Õ¹Ï ±z¥i¥h¬Ý¬Ý!
¹Ï12a¬OIV dupilumab vs aslan004 Pk ÁͶչÏ
2b ³]p¥Î0/1/2¶g¦U¤@°w¨Ó¤j°EASI¦Ü²Ä¥|¶g¬ù60%,³Ñ¤Uªº10%~20%¥i³Q´î±Ó°ÝÃD¡B ¾a«á±ªº°w¼Æ¨Ó¸É¡D
§Ú¹ïQ2W*400mgªº«H¤ß³Ì±j¡B Q4WªºIGA ??? |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2022/12/17 ¤U¤È 11:19:43
²Ä 5804 ½g¦^À³
|
¤Ñ©R¤j
¤£¥Î¾á¤ßÅé«°ÝÃD ³o½g±M§Q¬O2020¦~10¤ë1¤é¨ú±o---¦¬®×¬O2021¦~3¤ë16¤é¶}©l ÃĪ«°Ê¤O¾Ç¤è±¤½¥q¤£¥i¯à¨S¦³´x´¤ 2b Á{§É¤~´±¥ÎSC¥Ö¤Uª`®g
¤£¨ü²z½×ªº§ô¿£¡A¥»±M§Qµo©ú¤H»{¬°¡A»P Dupilumab ¬Û¤ñ¡AASLAN004 ¥i¥H¹ê²{¸û§Cªº C through¡A¦]¬° ASLAN004 ¹v¦V IL-13Ra1¡A¦Ó Dupilumab ¹v¦V IL-4Ra¡C¦bÅ餺¡AIL-13Ra1 ªº¼Æ¶q¤j¤j¶W¹L IL-4Ra ªº¼Æ¶q¡C (¦^¥h¬Ý2021¦~4¤ë¤½¥q²³ø P 11¤w´£¨Ñ¹v¦V¤£¦P¨üÅ骺¿¼Æ¼Æ¾Ú ( 60¿:3¿ )
³o·N¨ýµÛASLAN004»Ýn¸û§C¤ô¥ªº§ÜÅé¡A¦]¦¹ASLAN004 ªºÃĮľǯS¼xªí©ú ASLAN004 »P Dupliumab ¬Û¤ñ«D±`¦³§Q¡A¨Ãªí©ú ASLAN004 ¨C¤ëµ¹ÃĪvÀøª¢¯g©Ê¯e¯f¡]¦p²§¦ì©Ê¥Ö½§ª¢¡^ªº¼ç¤O
·í¤j©ó©Îµ¥©ó 600mg ªº ASLAN004 ³QÀR¯ß¤ºµ¹ÃÄ (10mg/kg) ®É¡A¥¦Åã¥Ü¥X 100% ªº¨üÅé¦û¾Ú©M¦bµ¹Ãīᤣ¨ì 1 ¤p®É¤º§¹¥þ§í¨î STAT6 ÁC»Ä¤Æ¡C³o¨Ç®ÄªG¦b³æ¾¯¶q ASLAN004 «áºû«ù¶W¹L 29 ¤Ñ¡Aªí©ú¨C¤ëµ¹ÃÄ¥i¯à¬O¥i¥H¹ê²{ªº¡C
ASLAN004 ¹ï IL-4 ©M IL-13 «H¸¹ªº§Ö³t§í¨î¤]¥i¯à¾ÉP²§¦ì©Ê¥Ö½§ª¢©M¹L±Ó©Êý³Ý±wªÌªº¯gª¬§Ö³t½w¸Ñ¡C
¥H¤W¶È¨Ñ°Ñ¦Ò |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/12/17 ¤U¤È 10:23:46
²Ä 5803 ½g¦^À³
|
¸É¥R¡G 1a 600mgx6¤H¸É¥R
¦³2¤H¡B¥i§¹¥þ§í¨î¦ô28¤Ñ ¦³1¤H¡B¥i§¹§í¨î¨ì25¤Ñ¡D ¦³2¤H¡B¥i§¹¥þ§í¨î¨ì18¤Ñ ³Ì«á1¤H¡B¥i§¹¥þ§í¨î¨ì13¤Ñ¡D
¦b¥H¤Uºô§}¤W¡B¥i¤U¸üÀɮסD¦³¦UºØÁÍ¶Õ¹Ï patents.google.com/patent/WO2020197502A1
¸g¹L0/1/2¶g¨C¶g¤@°w¡BÀ°§U¬Æ¤j¡B´X¥G¥i§¹¥þ¤ÏÀ³¨ì²Ä28¤Ñ¡D
300/400mg*Q2W ¡B·ÀI¤pÀ³¦³¤£¿ùªºÀø®Ä¡B¤×¨ä¬O400mg.
Q4W,600mg¥i¥u |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/12/17 ¤W¤È 11:22:51
²Ä 5802 ½g¦^À³
|
ASLAN004 1A °·±d¤Hx¥´¤@°wªºµ²ªG¡G¡]³ø§i¤¤¦³SCx600mgx6¤H¸Ô²Ó¨C¤H³ø§i¡^
pSTAT6 ©M RO ¡]IL13Ra1)´ú©wªºµ²ªG¦p¹Ï 2 ¦Ü 11 ©Ò¥Ü¡C ÀR¯ß¤º (IV) ¶¤¦Cªºµ²ªG¡]¹Ï 2 ¦Ü 6¡^ ªí©ú 0.1 mg/kg ¾¯¶q¯à°÷¦b 1 ¤p®É¤º¹ê²{´X¥G¥þ³¡¨üÅé¦û¾Ú ASLAN004 ªººÞ²z¡C µM¦Ó¡A³oºØ®ÄªG¨Ã¥¼«ùÄò¡ApSTAT6 ©M´åÂ÷¨üÅé¤ô¥¦Ê¤À¤ñ¦¹«á¤£¤[¶}©l¤W¤É¡C
0.3 mg/kg ¾¯¶qªí²{µy¦n¡A¹ê²{§¹¥þ¨üÅé§í¨î¡A«ùÄò¬ù 24 ¤p®É¡C µM¦Ó¡A¦¹«á pSTAT6 ©M´åÂ÷¨üÅé¤ô¥¦A¦¸Ã©w¤W¤É¡C
¬Û¤Ï¡A¦b 1 mg/kg ¾¯¶q¤ô¥¤U¡A¦b¥Î ASLAN004 ªvÀø«áÆ[¹î¨ì pSTAT6 ©M´åÂ÷¨üÅé¤ô¥«ùÄò§í¨î¬ù 1 ¶g¡]²Ä 8 ¤Ñ¡^¡C
±N¾¯¶q´£°ª¨ì 3 mg/kg ¶i¤@¨B±N³oºØ®ÄªG©µªø¦Ü¬ù 2 ¶g¡]²Ä 15 ¤Ñ¡^¡C
³oºØÁ`ÅéÁͶզb 10 mg/kg ¾¯¶q¤ô¥¤UÄ~Äò¡A¨ä¤¤¹ê²{¤F¤j¬ù 4 ¶g¡]²Ä 29 ¤Ñ¡^ªº§¹¥þ§í¨î¡C
¹ï©ó¥Ö¤U (SC) ¶¤¦C¡]¹Ï 8 ¦Ü 11¡^¡Aµ²ªGªí©ú 75 mg ¾¯¶q¯à°÷¦b¬I¥Î ASLAN004 «á 24 ¤p®É¤º¹ê²{´X¥G¥þ³¡¨üÅé¦û¾Ú¡C µM¦Ó¡A³oºØ®ÄªG¨Ã¥¼«ùÄò¡ApSTAT6 ©M´åÂ÷¨üÅé¤ô¥¦Ê¤À¤ñ¦¹«á¤£¤[¶}©l¤W¤É¡C
µM¦Ó¡A¦b ¡]SC¡^150 mg ¾¯¶q¤ô¥¤U¡A¦b¥Î ASLAN004 ªvÀø«áÆ[¹î¨ì pSTAT6 ©M´åÂ÷¨üÅé¤ô¥«ùÄò§í¨î¬ù 1 ¶g¡]²Ä 8 ¤Ñ¡^¡C
±N¾¯¶q´£°ª¨ì 300 ²@§J¶i¤@¨B±N³oºØ®ÄªG©µªø¦Ü¬ù 2 ¶g¡]²Ä 15 ¤Ñ¡^¡C
¹ï©ó 600 mg SC ¾¯¶q¤]Æ[¹î¨ìÃþ¦üªºµ²ªG¡C ¤UªíÅã¥Ü¤F±µ¨ü 600 mg SC µ¹ÃĪº¨ü¸ÕªÌÅ髹ï PD ªº¼vÅT¡G ªí 2 ¡V ¨ü¸ÕªÌÅ髹ï PD ªº¼vÅT¡G600 mg SC
PD:Pharmacodynamic ÃÄ®Ä SC¡G¥Ö¤Uª`®g IV¡GÀR¯ßª`®g
1¡A55085(½s¸¹¡^¡þ70.6¡]Åé«¡þ¤½¤ç¡^¡þFull PD response to¡]§¹¥þ§í¨î¨ì¡^15¤Ñ¡APD lost by day 29) ²Ä29¤Ñ®ÉÃĮĺɥ¢¡C§í¨î¯à¤OÂk¹s¡C
2¡B55088/65.3kg/15¤Ñ¡Apartial PD to day 29 ²Ä29¤Ñ®É¤´¦³³¡¥÷§í¨î.¦³³¡¥÷ÃĮġC
3¡B55092/76.3kg/15¤Ñ.PD lost by to day 29 ²Ä29¤Ñ®É¡AÃĮĬ°¹s§í¨î¯à¤OÂk¹s
4¡B55095/82.3kg/§¹¥þ§í¨î¨ì²Ä8¤Ñ¡Apartial PD to 15day ²Ä15¤Ñ®É¡A¦³³¡¥÷ÃĮġC
5¡B550958/76.3kg/15¤Ñ¡Apartial PD to 29day ²Ä29¤Ñ¤´¦³³¡¥÷ÃĮġC
6¡B55101/68.8kg/§¹¥þ§í¨î¨ì²Ä15¤Ñ¡C
³o¨Çµ²ªG¥i¯àªí©ú¼W¥[¨ü¸ÕªÌÅé«·|¹ï PD «ùÄò®É¶¡²£¥Ít±¼vÅT¡C
These results may suggest that increasing subject weight negatively impacts on PD duration.
The results of the pSTAT6 and RO assays are shown in Figures 2 to 11. The results for the intravenous (IV) cohorts (Figures 2 to 6) suggest that the 0.1 mg/kg dose was able to achieve almost total receptor occupancy within 1 hour of administration of ASLAN004. However, this effect was not sustained and pSTAT6 and % free receptor levels started to rise shortly thereafter. The 0.3 mg/kg dose performed slightly better, achieving complete receptor inhibition, which lasted for about 24 hours. However, pSTAT6 and % free receptor levels again steadily rise after this. In contrast, at the 1 mg/kg dosage level, a sustained inhibition of pSTAT6 and %free receptor levels was observed for about 1 week (Day 8) following treatment with ASLAN004. Raising the dosage to 3 mg/kg further extended this effect to about 2 weeks (Day 15). This general trend continued with the 10 mg/kg dosage level wherein complete inhibition was achieved for around 4 weeks (Day 29). For the subcutaneous (SC) cohorts (Figures 8 to 11), the results suggest that the 75 mg dose was able to achieve almost total receptor occupancy within 24 hour of administration of ASLAN004. However, this effect was not sustained and pSTAT6 and % free receptor levels started to rise shortly thereafter. However, at the 150 mg dosage level, a sustained inhibition of pSTAT6 and %free receptor levels was observed for about 1 week (Day 8) following treatment with ASLAN004. Raising the dosage to 300 mg further extended this effect to about 2 weeks (Day 15). A similar result was also observed for the 600 mg SC dose. The table below shows the influence of subject weight on PD for subjects dosed with 600 mg SC: Table 2¡V influence of subject weight on PD: 600 mg SC
patents.google.com/patent/WO2020197502A1
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/12/17 ¤W¤È 07:41:57
²Ä 5801 ½g¦^À³
|
ASLAN004¤§Q4W(¥|¶g¤@°w)
Y¨ÌASLAN004 1a°·±d¤H¸ê®Æ±À¦ô 400¤@600mg¦ô¶È¥i§¹¥þ§í¨î¬ù12.5~13.5¤Ñ 0/1/2/6/10/14¶gx¦Xp6°w
¥H¤U004®£©ñ¶}«°ªù¡B¦³·ÀI¡D ²Ä28~42¤Ñ(²Ä¥|~¤»¶g) ²Ä55~72¤Ñ(²Ä¤K~¤Q¶g) ²Ä83~93¤Ñ(²Ä¤Q¤G~¤Q¥|¶g)
IGA0,1/IEASI90µ¥Àø®Ä¤ñ¸û§xÃø¹F¦¨¡D
¥Ø«eY¥¼¸Ñª¼ªºIGA0,1¥§¡¤£¬Æ²z·Q¡B³Ì¥i¯à¥X²{°ÝÃDªº´N¥i¯à¦b¨âÓQ4WÁ{§É¡D
Q2W·ÀI«D±`¤p¡D
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2022/12/16 ¤U¤È 08:16:31
²Ä 5800 ½g¦^À³
|
¨È·à±d¤Sn°Ñ¥[°ê»Ú·|ij
¥Íª«¦X§@·|ij ASLAN Pharmaceuticals ºÞ²z¼h±N¥X®u©ó2023¦~1¤ë9¤é¦Ü13¤é¦bª÷¤s Marriott Marquis Á|¦æªº¥»¦¸·|ij¡A¨Ã³q¹L BIO Partnering ¦b½u¦X§@¥¥x°Ñ¥[»P§ë¸êªÌ©M¼ç¦b¦X§@¹Ù¦ñªº¤@¹ï¤@·|ij¡C
n¦b¥»¦¸·|ij¤Wµù¥U»PºÞ²z¼h·|±¡A½Ð³X°Ý¦¹Ãì±µ¡C
²Ä 12 ©¡¦~«× LifeSci ¦X§@¹Ù¦ñ¥ø·~ã¤J¬¡°Ê
ASLAN Pharmaceuticals ºÞ²z¼h±N©ó 2023 ¦~ 1 ¤ë 10 ¤é¦bª÷¤s°Ñ¥[¦¹¦¸¬¡°Ê¡A¨Ã»P¾÷ºc§ë¸êªÌÁ|¦æ¤@¹ï¤@·|ij¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2022/12/16 ¤U¤È 06:07:20
²Ä 5799 ½g¦^À³
|
ªYÄ£¤]¬O©|¥¼©MÃļt©|¥¼±ÂÅv´N¥ýñq¦³Àv¦X©ó |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2022/12/16 ¤U¤È 06:02:40
²Ä 5798 ½g¦^À³
|
©Î³\¶V¬O¸Ô²Ó¯u¹êªº¼Æ¾Ú¤~¯àµ¹¥X ¦w¥þ¤£¦YÁ«ªº»ù¿ú |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2022/12/16 ¤U¤È 05:09:19
²Ä 5797 ½g¦^À³
|
05/06¤½¥q¤½§i¦¨¥ß36Ó©Û¶Ò(¦¬®×)¤¤¤ß¡A¥[2Ó¤ë©Û¶Ò(¿z¿ï)¡A¥[4Ó¤ëªvÀø(¸ÕÅç)¡A¥[1Ó¤ë¼Æ¾Ú¾ã²z¡A111/12/06¥H«á¤½¥¬¸Ñª¼¼Æ¾Ú¡C ¤½¥q¤â¤W¦³¼Æ¾Ú¤F¡A¦Ó¥BÃÒ©ú§@TREK-DX ¦¨¥\ªº¾÷²v«Ü°ª¡C (§Y©ú¦~4¤ëTREK-AD¸Ñª¼¼Æ¾Ú¥¿¦Vªº¾÷·|«Ü¤j¡A¤~·|Äò§@TREK-DX) (Ãļtª¾¹DTREK-AD¸Ñª¼¼Æ¾Ú¥¿¦V¦Ó¤£¨ÖÁÊ??n©ì¨ìTREK-DX¸Ñª¼¼Æ¾Ú¥¿¦V¡A¤~¨Ó¥[»ù¨ÖÁÊ???Å޿褣¹ï)
¦b¬ü§@TREK-ADªº¦¬®×¤¤¤ß¡Aª½±µ®³¨Ó§@TREK-DX¡A§Y¬Ù¥h¦A§ä¦¬®×¤¤¤ßªº®É¶¡??? |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2022/12/16 ¤U¤È 04:28:33
²Ä 5796 ½g¦^À³
|
À³¸Ó¬O¦³¼Æ¾ÚÃÒ©ú¦³¾÷·|°µ³o¼Ë ªºÁ{§É·|¦¨¥\¤~³W¹ºªº ¦Ó¥BÁ{§Éªº¸êª÷¬O¦³³æ¦ì¥þÃB¸ê§U ?·|¬O¼ç¦bªº¶R®a?ÁÙ¬O·sªºª÷¥D §ÚÁÙ¬O¼ÖÆ[¬Ý«Ý³o¥ó¨Æ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2022/12/16 ¤W¤È 11:03:21
²Ä 5795 ½g¦^À³
|
³¯¤j¡A±j¯PÃhºÃ¤½¥q¥u·Qºû«ù¦b0.5¥H¤W¡AÃø¥H¤Wº¦¶W¹L1¶ô¡A«Ý2023/3/26«á¦A¼W¸ê¡A¥Hµ}ÄÀ¨È¬wªÑÅv¤ñ¨Ò¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2022/12/16 ¤W¤È 09:43:49
²Ä 5794 ½g¦^À³
|
«Ó¤j
¬ü°êªÑ¥«¤jº¦¡A¥L¤]¨S¸òµÛ¤ÏÀ³¡A
¬üªÑ¤j¶^®É¥L¸òµÛ¶^¡A²{¦bªÑ»ù¤@ª½±r
«Þ¾ú¥v§CÂI¡A
¥L̬һ⦳¤½¥qÁ~¤ô¡A¦ÛÀ³¾¨¥»¤À¼®¤O±q¤½¡A³o¬O¥L̬°¦Û¤v¤Î¤½¥qÀ³°µªº¨Æ±¡
¨C·í¤½¥q¤½¥¬°T®§©Î°Ñ¥[°ê»Ú·|ij»¡©ú«á¡A
ªÑ»ù¬Ò¬O¤Ï¦V¤ÏÀ³¡A¥«³õªº¸ÑŪ§¹¥þ¤£¦P¡A¥O¤H¶O¸Ñ¡A |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2022/12/16 ¤W¤È 07:46:27
²Ä 5793 ½g¦^À³
|
ÁöµM§Ú¤]¹ï¨È·à±d«Ü¥¢±æ ¦ý¬Q¤Ñ¯uªº¬O«D¾Ô¤§¸o ¬üªÑ¼É¶^¡A¤p«¬ªÑ³£¤£¦n ¬Û¤Ï¦a§Úı±o¨È·à±d¦³½T¹ê¤½§i·s»D¬O¦nªº ¦Ü¤Ö¤½¥qÁÙ¦³¦b§V¤O¡A§Æ±æ¤´¦b |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2022/12/16 ¤W¤È 01:24:55
²Ä 5792 ½g¦^À³
|
¤S¬O¤@¼Ë±¡§Î
¨È·à±d¤½¥q«Å¥¬«n°T®§
·í¤ÑªÑ»ù¤@©w«®À
¤µ¤Ñ¤£¨Ò¥~«ÅºÙ¤wµn¿ý¬ã¨s²Ä¤@¦ì¯f¤H
²{¦bªÑ»ù«®À10%¥H¤W
¯u¬O¼Ð·Ç韮µæ¦¬³ÎªÑ¡A³Î¦n³Îº¡ ¼Ð·ÇªÅ´ß¤½¥q |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/12/15 ¤U¤È 08:38:09
²Ä 5791 ½g¦^À³
|
ASLAN Pharmaceuticals «Å§G¦b Dupilumab ¸g¾úªº¯SÀ³©Ê¥Öª¢±wªÌ¤¤¶i¦æ Eblasakimab ¬ã¨s¿z¿ïº¦ì±wªÌ ¨È´µÄõ»sÃĦ³¤½¥q 2022 ¦~ 12 ¤ë 15 ¤é¬P´Á¥|±ß¤W 8:00¡P7 ¤ÀÄÁ¾\Ū ¨È´µÄõ»sÃĦ³¤½¥q
¦b Dupilumab ¦³¸gÅ窺¯SÀ³©Ê¥Öª¢±wªÌ (TREK-DX) ¬ã¨s¤¤¨Ï¥Î Eblasakimab ªº¸ÕÅç±N¦b´X¥G¨S¦³¦w¥þªvÀø¿ï¾Üªº±wªÌ¸sÅ餤µû¦ô eblasakimab
¸Ó¬ã¨s±N¦b¥_¬ü©Û¶Ò 75 ¦W±wªÌ¡A¹wp±N¦b 2024 ¦~²Ä¤@©u«×Àò±o³»½uµ²ªG
¬ã¨s¸êª÷¥R¨¬¡A¹ï¤§«e³ø§iªº²{ª÷¶]¹D¨S¦³¼vÅT
¨Ó¦Û TREK-DX ©M TREK-AD ªº¼Æ¾Ú¥i¥H¤ä«ù eblasakimab ¥Î©ó¥Íª«¾Çªìªv©M¦³¸gÅ窺 AD ±wªÌ
ASLAN Pharmaceuticals Announces First Patient Screened in Study of Eblasakimab in Dupilumab Experienced Atopic Dermatitis Patients ASLAN PHARMACEUTICALS LIMITED Thu, December 15, 2022 at 8:00 PM¡P7 min read ASLAN PHARMACEUTICALS LIMITED ASLAN PHARMACEUTICALS LIMITED The TRials with EblasaKimab in Dupilumab eXperienced atopic dermatitis patients (TREK-DX) study will evaluate eblasakimab in a patient population with few safe treatment options
The study will enroll 75 patients in North America with topline results expected in the first quarter of 2024
Study is fully funded with no impact on previously reported cash runway
Data from TREK-DX and TREK-AD could support the use of eblasakimab for both biologic naïve and experienced AD patients |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/12/15 ¤U¤È 05:07:29
²Ä 5790 ½g¦^À³
|
2b Á{§É 400mg xQ2W¡A¼ÒÀÀ
2b ®Ú¾ÚASLAN004 1b 400mg x8¶gx¤@°w¡þ¶g¡A¦@8°w¡AN=6 (2021/03/1¤½¥¬¸ê®Æ¡^
ir.aslanpharma.com/static-files/5af23249-0b59-4bb1-95eb-199556171feb
1.¥§¡EASI°´T⋯¡]lb=2b) ²Ä¤@¶g¡]²Ä8¤Ñ ¡^15% ²Ä¤G¶g¡]²Ä15¤Ñ¡^ 45% ²Ä¤T¶g¡]²Ä22¤Ñ¡^ 55%⋯¡]TRAC°´T¤w¹F¬Û¹ï§CÂI¬ù73%¡^
⋯⋯¤@¤@¤@ 2b Á{§É¡A²Ä23¤Ñ¡ã²Ä30¤Ñ¡A¼ÒÀÀ
300mg ¦b°·±d¤H1aÁ{§É²Ä8¤ÑIL13Ra1=0%¡A²Ä15¤Ñ=30%¡]¦ôp§¹¥þ§í¨î¤O逹²Ä13¤Ñ¡^ 600mg ¦b²Ä8¤ÑIL13Ra1=0%,²Ä15¤Ñ10%(¦ôp§¹¥þ§í¨î¤O逹²Ä14¡P4¤Ñ¡^ 400mg¦b1A ²Ä8¤ÑIL13Ra1=0%,²Ä14¤Ñ¦å²G¤¤¥i¯à¦³23%ªº¡A¡]¦ôp§¹¥þ§í¨î¤O逹13¡P5¤Ñ¡^
«h2bÁ{§É400mg§¹¥þ§í¨î¥i¥Ñ²Ä0¤Ñ¡ã²Ä27¡P5¤Ñ¡A¦å²G¤¤ªºIL13Ra1¥i«O«ù0%ª¬ºA¡C ¥§¡ªºEASI°´T¦ô62%¡AEASI50¦ô¤w¹F80%⋯⋯⋯⋯EASI75¦ôp>50% ¥Ñ©ó80%ªº±wªÌ¤w¸g¹FEASI50¡A,«h²Ä29¤ÑªºÀø®Ä³Ì¤j¥i¯à´N°±¯d¦b²Ä27¡P5¤Ñ¡A¦p²Ä8¶g¡ã11¶gªºTRAC´X¥Gºû«ù¦b§CÀÉ¡C ¦b²Ä29¤Ñªº²Ä¥|°w¬I¥´«á«Ü§Ö´N¦^´_§¹¥þ§í¨î¡C
µ²½×¡G2b ²Ä29¤ÑªºÀø®Ä¡AEASI¥§¡°´T¦ôp¥u´î3%¥ª¥k¡A¥i¹F°62%¡C ¨Ì¦¹Ãþ±À 2b ²Ä¤¶g¡]36¤Ñ¡^68% 2b ²Ä¤»¶g¡]43¤Ñ¡^71%(À³¸Ó¥i¸É¨¬¤§«e¬y¥¢ªº¤Ö¶qÀø®Ä¡A¦^¨ìIbªº¤ô·Ç¡C
⋯⋯⋯⋯ 1b ²Ä¥|¶g¡]²Ä29¤Ñ¡^65%⋯¡]¦ôEASI50 ¤w¹F83%¡^ ²Ä¤¶g¡]²Ä36¤Ñ¡^71%⋯¡]¬Û¹ï§CÂI¡AEASI75¦ô67%¡^ ¡K¡K¡K¡K 1b=2b
²Ä¤»¶g¡]²Ä43¤Ñ¡^73%⋯ ²Ä¤C¶g¡]²Ä50¤Ñ¡^75%⋯¡]³Ì§CÂI¡AEASI90¦ô¤w¹F67%¡^ ²Ä¤K¶g¡]²Ä57¤Ñ¡^74%
2.¨ä¥L«ü¼ÐÀø®Ä¡G EASI50=83% EASI75=67% EASI90=67%
TRAC°´T¡G aslanpharma.com/wp-content/uploads/2022/09/EADV-2022-Biomarker-Poster_P0243_upload.pdf
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/11/12 ¤U¤È 07:52:46²Ä 5764 ½g¦^À³ Lebrikizumab 2b ¦PÀø®Äªº¹F¦¨³t«×§C©óDupilumab 2a ,¦ý²Ä16¶g¦³¬ÛªñªºÀø®Ä¡C ASLAN004 ¨C¶g¤@°w¡A«e8¶gEASI¤U°Àø®Ä³t«×©MDupilumab¬Ûªñ¡C
¤@¤@¤@¤@
Dupilumab 2a N=110 QWx12¶g Vs Lebrikizumab 2b Q2Wx16¶gN¡×75:52
1¡AEASI50 Dupilumab.//Lebrikizumab ²Ä¤T¶g 55%// ²Ä¥|¶g 65%//52% ²Ä¤¶g 85%¡]¨£°ªÂI¡^// ²Ä¤»¶g 85%// ²Ä¤K¶g 85%//70% ²Ä¤Q¤G¶g85%//81%¡]¨£°ªÂI¡^ ²Ä¤Q¤»¶g¡X¡X//81%
Dupilumab ¥i¦P®Éªý¾×Âù¼Ð¹vIL4/IL13¡A©Ò¥H¦b²Ä¤¶gEASI50´N¹F°ªÂI85%¦ÓLebrikizumab¥u¯àªýÀÉIL13¤Î³¡¤ÀlL4©Ò¥Hª½¨ì²Ä¤Q¤G¶g¤~¹F81%°ªÂI¡C
¤G¡AEASI75 Dupilumab.//Lebrikizumab
²Ä¥|¶g 35%//30% ²Ä¤K¶g ¡X//42% ²Ä¤Q¤G¶g62%//62%¡]°ªÂI¡^ ²Ä¤Q¤»¶g¡X¡X//61%
¤T¡BIGA 0,1 Dupilumab.//Lebrikizumab
²Ä¥|¶g 18%//18% ²Ä¤K¶g ¤@¤@//30% ²Ä¤Q¤G¶g40%//41% ²Ä¤Q¤»¶g¡X¡X//43%¡]°ªÂI¡^ Lebrikizumab ªý¾×°T®§¯à¤O®Ä¯à¸û®t¡A¦ý®É¶¡©Ôªø¨ì16¶g¡A¤´¥i¸É¨¬IGA0,1ªºÀø®Ä¡C
www.nejm.org/doi/10.1056/NEJMoa1314768 ¹Ï¤@ Dupilumab
www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&p=PMC3&id=7142380_jamadermatol-156-411-g002.jpg
¹Ï¤G¡þªí¤G Lebrikizumab
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/12/13 ¤U¤È 08:11:50
²Ä 5789 ½g¦^À³
|
aslanpharma.com/news/?cat=publications
ASLAN004 1b mITT ¦U¶µ«ü¼Ð¬ù¦b²Ä¤¡ã¤»¶g¨£³Ì¨Î¸¨ÂI¡C¥B¬Ò赢¹LLebrikizumab ²Ä16¶gªº¼Æ¾Ú¡C
¥H¤W¸É¥R»¡©ú¡C
¦ÓLebrikizumab¡]µLªk§¹¥þ«ÊªýIL4/IL13¬G¡^ «n«ü¼Ð³Ì¨Î¸¨ÂI¤j¦h¥X²{¨ì²Ä12¡ã16¶g¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/12/13 ¤U¤È 05:42:09
²Ä 5788 ½g¦^À³
|
www.almirall.com/documents/portlet_file_entry/4257831/300322_ORI+Lebri+pres+ENG+%2B+pres+vf.pdf/5ad7034f-0dd9-492f-eb83-1515071417de
Lebrikizuma 2Ó¤T´ÁÁ{§É,¨C¨â¶gªºÁͶչÏ(2022/03/30)---Almirall ¤½¥q(¼Ú¬w°Ï¾P°â¤½¥q) °ª峄¾P°â:4.5»õ¼Ú¤¸
¥Dn«ü¼Ð:EASI75//IGA0,1 ¦¸n«ü¼Ð:EASI90 //Pruritus NRS ≥4-point improvementa from baseline //Sleep loss NRS ≥2-point improvementa from baseline //Quality of life: DLQI ≥4-point improvementa from baseline --------------------------------------------------------------------------- ¤ñ¹ïASLAN004 1b MITT ¹Ï«á,¹ïASLAN004 2B Á{§Éµ²ªG·|§ó¦³«H¤ß. §ÚÌ«e¤T¶g¬Ò¤j´T»â¥ý¦]¬°§¹¥þ«ÊªýIL4/IL13°T®§¶Ç»¼, ²Ä¥|¶g«áÁͶÕÀ³·|©MLebrikizumab ¨«¶Õ¬Ûªñ.¦]¬°ASLAN004¨C¤G¶g¥i¯à¶È§¹¥þ«ÊÂê7¤Ñªº³¡¥÷«Êªý, ¦ý¦]«eASLAN004´Á3~4¶g,¤w¤j´T´î±Óªñ50%,¥B¥Íª««ü¼ÐTRACC¤w°¦Ü©³ÂI(³Ì°ª°ªñ80%). ²Ä¥|¶g«áASLN004 2B À³¦p¯à¦pLebrikizumab ¦b(¥þµ{)³¡¥÷«ÊÂꪺª¬ªp¤U,¦U«ü¼Ð¯à³v¨B©Ô°ª,¹FÀ³¦³¤ô·Ç.
³Ì«á¦p¤½¥q©Ò¹w´úÀø®Ä(IGA 0,1)8% °ª©óDupilumab 2¶g¼Ð·ÇªvÀø¾÷·|°ª.
¥Ø¼Ð»ù¦pú³°Ó:4~7¬ü¤¸/ªÑ¾÷·|°ª
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/12/13 ¤U¤È 02:43:54
²Ä 5787 ½g¦^À³
|
¥x¤jÂå°|¥Ö½§¬ì¥D¥ô¦¶®a·ì¡@¤¤««×²§¦ì©Ê¥Ö½§ª¢±wªÌ¡@±`¨£ªº5¤j¯gª¬
¥x¤jÂå°|¥Ö½§¬ì¥D¥ô¦¶®a·ìÂå®vªí¥Ü¡A¤¤««×²§¦ì©Ê¥Ö½§ª¢±wªÌ¦³5¤j¯gª¬¡AÅý¥¦ÌÅܦ¨¡u§ì¨g²§±Ú¡v¡C
1. Äo¡G¬ã¨s³ø§i«ü¥X6¦¨¥H¤W¤¤««×±wªÌ¥Ö½§¦b¤@¤Ñ¤¤µoÄo¶W¹L12¤p®É¡A«ùÄòµoÄoÅý57%±wªÌ·P¨ì§ì¨g¡C 2. µh¡G¬ã¨s«ü¥X¶W¹L75%¤¤««×²§¦ì©Ê¥Ö½§ª¢±wªÌ·|·P¨ì¤¤«×¦ÜÄY«ªº¯kµh»P¤£¾A¡C 3. ¬y¦å¡G¬ã¨sÅã¥Ü¬ù4¦¨±wªÌ¦b¹L¥h¤@¶g¦Ü¤Ö¦³¤@¤Ñ¥Ö½§¬y²Õ´²G©Î¬y¦å¡C 4. ¥¢¯v¡G¬ã¨sÅã¥Ü¥b¼Æ±wªÌ¦b¹L¥h¤@¶g¦Ü¤Ö¦³¤@¤ÑºÎ¯v¨ü¨ì¼vÅT¡C 5. ¥¢±±¡G¬ã¨sÅã¥Ü2¦W««×²§¦ì©Ê¥Ö½§ª¢±wªÌ¤¤´N¦³1¦W¡A¨C¤Ñ¤ÏÂШü¨ì¯e¯f¯gª¬©ÒW¡A25%±wªÌı±o¥L̪º¯e¯f¥¢±±¡A¬Æ¦Ü30%ªº±wªÌ¦]¬°©Ó¨üµÛ¥¨¤jªº¤ß²zÀ£¤O¦Ó³´¤J¼~Æ{¡C
°£¤F¥H¤Wªº5ÂI¥~¡A¥Ö½§·|¬y¦å¤Î²Õ´²GÅý±wªÌ·P¨ìÀª§¼¡A·Qn¾B±»¦Û¤vªº±w³¡©ÎÁקK¶â¥L¤HªÏÅ鱵IJ¡C
¥xÆW²§¦ì©Ê¥Ö½§ª¢±wªÌ¡@¥Í¬¡«~½è½Õ¬d
¦¶®a·ìÂå®v¤À¨É¡A¤µ¦~°w¹ï¥xÆW²§¦ì©Ê¥Ö½§ª¢±wªÌ¶i¦æªº¥Í¬¡«~½è½Õ¬d¤]µo²{Ãþ¦üµ²ªG¡A¤ÀªR150¦ì¦¨¤H±wªÌªº³X°Ý«á¡Aµo²{²§¦ì©Ê¥Ö½§ª¢ÄY«¼vÅT¦U¥Í¬¡±¦V¡A¦p¤é±`¬¡°Ê¡B¤u§@¾Ç²ß¡B¤H»ÚÃö«Yµ¥¡A¯fªp¶VÄY«¡B¥Í¬¡«~½è¶V®t¡C©Ò¦³±wªÌªººÎ¯v«~½è³£¤£¦n¡A¥ÎÃÄÀ°§U¤JºÎªº¤ñ¨Ò¬O°ê¤Hªº1.5¿12¡A¥B¤u§@¥Í²£¤O¤]¨ü¼vÅT¡A4¦W±wªÌ´N¦³1¦W¨S¤u§@¡A¥¢·~²v¬°¥þ°ê¥§¡ªº7¿¡C¤£¦ý¨S¦¬¤J¡A75%±wªÌÁÙ·|±µ¨ü¶Ç²ÎÀøªk¡B°·±d¹«~µ¥¨ä¥L¤èªk¡A§ó¬O¥[«±wªÌªºt¾á¡C
¤¤««×²§¦ì©Ê¥Ö½§ª¢ªvÀø¤T³¡¦±
¦¶®a·ìÂå®vªí¥Ü¡A¤¤««×²§¦ì©Ê¥Ö½§ª¢ªvÀø¦³¤T³¡¦±¡F²Ä¤@³¡³q±`·|¥ý«Øij±wªÌ¨Ï¥Î¨Å²G¡B«OÀ㾯¤Î¥~¥ÎÃþ©T¾JÃĪ«©M§Ü²Õ´ÓiÃĪ«¡A¦ý52%ªº±wªÌ¤£º¡·N¥~¥ÎÃþ©T¾J¹ï¯gª¬±±¨îªº®ÄªG¡A¥Bªø´Á¨Ï¥Î«á·|¦³¨Ï¥Ö½§ÅÜÁ¡ªº°Æ§@¥Î¡C
²Ä¤G³¡³q±`·|¨Ï¥Î§K¬Ì§í¨î¾¯ÃÄ»I¤Î·Ó¥úªvÀøµ¥¤èªk¡A«eªÌ·|³y¦¨¥Ö½§ªº¨`¼ö·P»P·kÄo¡A¦³40%ªº±wªÌ·P¨ì¦³°Æ§@¥Î¤Î63%±wªÌ¤£º¡·N§K¬Ì§í¨î¾¯ÃÄ»I¹ï¯gª¬±±¨îªº®ÄªG¡F«áªÌ¦³60%ªº±wªÌ¤£º¡·N·Ó¥úªvÀø±±¨îªº®ÄªG¡C
²Ä¤T³¡«h¨Ï¥Î¤F§K¬Ì½Õ¸`¾¯¨Ó±±¨îµoª¢©Î¹L±Ó¤ÏÀ³¡A¦ýªø´Á¨Ï¥Î§K§í¨î¾¯¥i¯à·|¼vÅT¨x¡BµÇ¥\¯à¡A¶·§@©w´Áªº¦å²GÀˬd¡C¦b¨Ï¥Î§K¬Ì½Õ¸`¾¯ªº±wªÌ¤¤¡A¤´¦³53.4%ªº¤ñ¨Ò¡A¯fªp³QÂå®vÂkÃþ¬°±±¨î¤£¨}¡C¦Ó8¦¨ªº²§¦ì©Ê¥Ö½§ª¢±wªÌ¹ï©óªvÀø¨Ã¤£º¡·N¡A§ó¦³4¦¨±wªÌ§ä¹L5Ó¥H¤WÂå®v¡C¦Ó³Ì·sªº¥Íª«»s¾¯ÁöµM¦³®Ä¡A¦ý¤@°w»Ýn28000¡A¹ï±wªÌ¨Ó»¡¬O¤@µ§¤£¤pªºt¾á¡C
§ì¨g²§±Ú¡G»{ÃѤ¤««×²§¦ì©Ê¥Ö½§ª¢ - Heho°·±d heho.com.tw/archives/28443 |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/12/13 ¤U¤È 01:06:24
²Ä 5786 ½g¦^À³
|
¥Ñ¥H¤U¬ü°ê¾÷ºc(¹ï¨R°òª÷),¹ïASLN 100¤dªÑ¥H¤W«ùªÑ 2022Q3 VS 2021Q1(¥]¾P4¬ü¤¸/ªÑ) ²Îp
21,750¤dªÑ VS 27,000 ¤dªÑ
½æ¶W: 5,250¤dªÑ, ½æ¶W¦û¾÷ºc«ùªÑ5,250/27000=19.4%, ½æ¶W¦ûªÑ¥»5,250/70,000=7.6%
¨ä¤¤¶R¶W³Ì¦hªº¬O : TANG CAPITAL MANAGEMENT LLC 5,654,925 CITADEL ADVISORS LLC ¬ù2,000,000 -------------------------------------------- ¨ä¤¤½æ¶W³Ì¦hªº¬O ORBIMED ADVISORS LLC 2,520,000 LOGOS GLOBAL MANAGEMENT LP 2,300,000(½æ¥ú) MANGROVE PARTNERS 2,178,063(½æ¥ú) LUMINUS MANAGEMENT LLC 1,753,800(½æ¥ú) ASYMMETRY CAPITAL MANAGEMENT, L.P. 1,352,57(½æ¥ú)
whalewisdom.com/stock/asln
¤@.2022//Q3 ¬ü°ê¾÷ºc¹ïASLN «ùªÑ
TANG CAPITAL MANAGEMENT LLC 5,654,925 RTW INVESTMENTS, LP 3,015,987 VIVO CAPITAL, LLC 2,840,909 CITADEL ADVISORS LLC 2,665,139 TEMASEK HOLDINGS (PRIVATE) LTD 1,678,075 MILLENNIUM MANAGEMENT LLC 1,589,369 SIO CAPITAL MANAGEMENT, LLC 1,270,758 IKARIAN CAPITAL, LLC 820,455 SABBY MANAGEMENT, LLC 499,045 BARCLAYS PLC 471,270 RENAISSANCE TECHNOLOGIES LLC 365,800 WATERFRONT WEALTH INC. 360,500 MORGAN STANLEY 150,983 MYDA ADVISORS LLC 150,000 PLATINUM INVESTMENT MANAGEMENT LTD145,558
¦Xp¬ù 21,750,000
¤G.·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2021/5/19 ¤U¤È 03:50:19²Ä 4214 ½g¦^À³ 2021¦~3¤ë31¤é ¦b¬ü¾÷ºc§ë¸êASLN ADR ©ú²Óªí
whalewisdom.com/stock/asln
RTW INVESTMENTS, LP 3,250,000 VIVO CAPITAL, LLC 2,840,909 ORBIMED ADVISORS LLC 2,520,000 LOGOS GLOBAL MANAGEMENT LP 2,300,000 MANGROVE PARTNERS 2,178,063
LUMINUS MANAGEMENT LLC 1,753,800 TEMASEK HOLDINGS (PRIVATE) LTD 1,678,075 SIO CAPITAL MANAGEMENT, LLC 1,448,508 ASYMMETRY CAPITAL MANAGEMENT, L.P. 1,352,57 MILLENNIUM MANAGEMENT LLC 1,246,275 IKARIAN CAPITAL, LLC 1,224,516
SABBY MANAGEMENT, LLC 817,165 DAFNA CAPITAL MANAGEMENT LLC 677,500 CITADEL ADVISORS LLC 652,511 PLATINUM INVESTMENT MANAGEMENT LTD 514,984 KNOTT DAVID M 437,412 MONASHEE INVESTMENT MANAGEMENT LLC420,000 GOLDMAN SACHS GROUP INC 407,464 PARKMAN HEALTHCARE PARTNERS LLC 325,000 RENAISSANCE TECHNOLOGIES LLC 258,467 AFFINITY ASSET ADVISORS, LLC 200,000 MYDA ADVISORS LLC 200,000 CAAS CAPITAL MANAGEMENT LP 150,000 BOOTHBAY FUND MANAGEMENT, LLC 130,920 BARCLAYS PLC 128,586
¦Xp ¬ù27,000,000 , 38.5%(27,000/70,000) |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/12/13 ¤W¤È 09:54:49
²Ä 5785 ½g¦^À³
|
¥V©u²§½§µo§@¡u§O§ì¤F¡v¡I ¥Ö½§¬ìÂå®v±Ð¤T©Û¤£¦A¯}¥Ö¬yÁw ³¯ ¶v³Í 2022¦~12¤ë11¤é ¶g¤é ¤U¤È2:00
¶×¬y·s»Dºô°OªÌ³¯¶v³Í¡þ¥x¥_³ø¾É
ÄoÄo¡A§O¦A§ì¤F¡I³o¬O¥V©u¥Ö½§¬ì¶E¶¡³Ì±`Å¥¨ìªº¹ï¸Ü¡AÂù©MÂå°|¥Ö½§¬ìÂå®v¬I©É½åªñ´Á´N¦¬ªv¤@¦W5·³¨kµ£¦]²§¦ì©Ê¥Ö½§ª¢µo§@¡A¾ã±ß¤£°±§ìÄo¡AµLªk¤J¯v¡A¤£¥u§ì¨ì¯}¥Ö¬y¦å¡A¬Æ¦Ü¥X²{¶Ë¤fµoª¢¡B¬yÁwµ¥²Óµß·P¬Vªº±¡ªp¡A¥þ¨¥¬º¡·s¶ˤf¡CÂå®v´£¿ô¡A¥®É¥i¥H¥[±j«O·Ã¡BÁקK¨ë¿E¡B»·Â÷¹L±Ó쬰·ÓÅ@ì«h¡C
²§¦ì©Ê¥Ö½§ª¢¤W¨¡A°ê¤ºªù¶EÆ[¹î¡A¤£¤Ö¤pªB¤Í±`¦]·kÄoÃø@¡AµLªkÀò±o¥R¨¬ºÎ¯v¡Aºë¯«¤£ÀÙªº±¡ªp¤U¡A¶i¦Ó¼vÅT¨ì¥Õ¤Ñªº¶¼¹¡B¾Ç²ßµ¥¬¡°Ê¡A¥t¥~¡A®aªø¤]±`·P¨ü¨ìº¡º¡ªº¯h
¬I©É½å¡A²§¦ì©Ê¥Ö½§ª¢¬O¥xÆW±`¨£ªº¥Ö½§¯e¯f¡A¬O¤@ºØ¦h°ò¦]¿ò¶Çªºµoª¢¯e¯f¡A¥Dn¬O¥Ñ¥ý¤Ñ©Ê§K¬Ì½Õ¸`²§±`¤Îªí¥Ö¤º¦b½Õ±±¥¢½Õ©Ò¤Þ°_¡C®Ú¾Ú²Îp¡A¥xÆW¦³¶W¹L200¸U¦W±wªÌ¡A«Ü¦h¤H±qÀ¦¥®¨à®É´Á´N¶}©lµo¯f¡A°£¤FÄY«·kÄo±a¨Óªº¤£¾A¤§¥~¡A¬õ´³¡B¥C¯l¤Î¤ÏÂеo§@³y¦¨ªº¥Ö½§aÄö¤Æ¡A¤]¶¡±µ¼vÅT¨ì±wªÌ¦Û«H¡BªÀ¥æ¤Î¤H»ÚÃö«Yµo®i¡A©ö´_µoªº¯S©Ê¤£¶ÈÅý¯f¤Í¹ïªvÀø¥¢¥h´Á«Ý¡A¬Æ¦Ü²£¥ÍÀ£¤O»Pt±±¡ºü¡C
ªù¶E¤¤´N´¿¦³±wªÌ¦]¤â³¡¦³¤j¤ù¯f¨_¦Ó¤£´±»P¤H´¤¤â¡Aªø¤[¤U¨ÓºtÅܬ°ªÀ¥æ»Ùê¡A¥[¤W¨ä®ø·¥ºA«×¡A¦b¨D¾Ç¤Î¨D¾¹Lµ{¤¤ÀWÀW¸I¾À¡C
¬I©É½å«ü¥X¡A²§¦ì©Ê¥Ö½§ª¢ªº§Î¦¨©M¨â¤j¦]¯À¦³Ãö¡Aº¥ý¬O¡uªí¥Ö«Ì»Ù¯Ê³´¡v¹³¬O¡AÅÖ»E³J¥Õ¯Ê³´¡B¯«¸gñQÓi¤£¨¬µ¥µ¥¡F¨ä¦¸¬O¡u§K¬Ì²ÓM¹L«×¤ÏÀ³¡v¡A·í¯S©w§K¬Ì²ÓM¥H¤Î¢â²ÓM¹L«×¬¡¤Æ¡A´N·|³y¦¨¥Ö½§µoª¢¡A§Î¦¨ªx¬õ¡BµoÄo¡B²æ®hµ¥Á{§Éªí²{¡C
ȱoª`·Nªº¬O¡A¬I©É½å»¡¡A²§¦ì©Ê¥Ö½§ª¢ªº¯f¨_¤À¥¬·|ÀHµÛ¦~ÄÖ¦Ó¦³©Ò¤£¦P¡A¦bÀ¦¨à¤Î¥®µ£®É´Á¡A¯f¨_¥Dn¤À¥¬¦bÁy¡B¤â¨y¤Î½¥»\¡F¦~¬ö¸û¤jªº¤p«Ä¡A«h¦b¥|ªÏÅs¦±³B¥X²{ºC©ÊaÅ~¤Æ¯f¨_¡F¨ì¤F«C¤Ö¦~©Î¦¨¤H¡A¤Ö³¡¤À¯f±w¥i¯à·|¦nÂण¦A´_µo¡A¦ý¤j¦h·|«ù¥©Î§ïÅÜ«¬ºA¡A¬Æ¦ÜÅܦ¨ÄY«ªº§½³¡¯f¨_©Î¥þ¨©Ê»´«×¯f¨_¡C
¬I©É½å«Øij¡A¥®µ£°£©w´Á´NÂå±µ¨üªvÀø¡Aµo¯f®É¥t¥i¥ý±q°·Å¡B³q·¶}©l¡A¨Ã§Q¥Î¨ä¥L¨Æª«Âಾª`·N¤O¥H§K§ì¶Ë¡A¥±`«hª`·N«O·Ã¡BÁקK¨ë¿E¤Î»·Â÷¹L±Óìµ¥·ÓÅ@ì«h¡F¦Ü©ó¨àµ£©Î«C¤Ö¦~¡A¦b¤ß²z¤ä«ùªº³¡¤À±o¯S§Oª`·N¡A¹³¬O«C¬K´ÁªºµJ¼{¡A©Î¬O¨D¾Ç¡B·Ç³Æ¦Ò¸Õ¹Lµ{¤¤ªºÀ£¤O³£¦³¥i¯àIJµo¡A°£¥HÃĪ«±±¨î¡B§ïµ½¯fªp¥~¡A¥²n®É¤]¥i´M¨D¤ß²z¿Ô°Ó¨ó§U¡A©Î¬O§ä¨ì¾A¦X¤è¦¡§çµo¤º¤ßÀ£¤O¡A¹³¬O¾A«×¹B°Ê¡B³W¹º¨ã³Ð³y©Êªº¥ð¶¢¬¡°Ê©Î¥[¤J¦P¾«¹ÎÅé¤À¨É¤ß±¡µ¥¡C
·Ó¤ù¨Ó·½¡GÂù©MÂå°|
¤Ñ§N
¡i¤å³¹Âà¸ü½Ðµù©ú¥X³B¡j
-~B/aD0yMDA7dz02NzA7YXBwaWQ9eXRhY2h5b24-/s.yimg.com/os/creatr-uploaded-images/2022-12/3dbc4bf0-76d7-11ed-bbfc-88e626aa2a99
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/12/12 ¤U¤È 04:10:35
²Ä 5784 ½g¦^À³
|
Lebrikizumab ¤G½u(¦³Dupilumab¨Ï¥Î¸gÅç)¤¤-««×AD ¤T´ÁÁ{§É120¤H,§Y±N¶}©l.¹wp12Ӥ맹¦¨.
¤w¤½§G16Ó¬ü°ê¦¬®×¤¤¤ß:
ASLAN004 ¤G½u(¦³Dupilumab¨Ï¥Î¸gÅç)¤¤-««×AD ,¤G´Á, ¹wp12¤ë©³§¹¦¨²Ä¤@Ó©Û¶Ò.
¥H¤W¤GÓÁ{§É´X¥G¦P®É©l
--------------------------------------- A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab
clinicaltrials.gov/ct2/show/NCT05369403?term=Lebrikizumab&draw=2&rank=3
|
|
¡@ |
¦^°Q½×°Ï1¶ |
<< 801 ~ 900 «h¦^ÂÐ >> |